
The following have been reloaded with a version change:
  1) GCCcore/8.3.0 => GCCcore/9.3.0
  2) binutils/2.32-GCCcore-8.3.0 => binutils/2.34-GCCcore-9.3.0
  3) zlib/1.2.11-GCCcore-8.3.0 => zlib/1.2.11-GCCcore-9.3.0

2021-01-24 03:24:06 | INFO | fairseq_cli.generate | Namespace(all_gather_list_size=16384, beam=5, bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', cpu=False, criterion='cross_entropy', data='../../../data-bin/custom_EMEA/short_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eval_bleu=True, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, left_pad_source='True', left_pad_target='False', lenpen=1, load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_sentences=128, max_source_positions=1024, max_target_positions=1024, max_tokens=None, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, momentum=0.99, nbest=1, no_beamable_mm=False, no_early_stop=False, no_progress_bar=False, no_repeat_ngram_size=0, no_seed_provided=True, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer='nag', path='../checkpoints/EMEA_15/checkpoint_best.pt', prefix_size=0, print_alignment=False, print_step=False, profile=False, quantization_config_path=None, quiet=False, remove_bpe='@@ ', replace_unk=None, required_batch_size_multiple=8, results_path=None, retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, score_reference=False, scoring='sacrebleu', seed=1, shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, target_lang=None, task='translation', temperature=1.0, tensorboard_logdir='', threshold_loss_scale=None, tokenizer=None, tpu=False, truncate_source=False, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, warmup_updates=0, weight_decay=0.0)
2021-01-24 03:24:07 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-01-24 03:24:07 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-01-24 03:24:07 | INFO | fairseq.data.data_utils | loaded 320 examples from: ../../../data-bin/custom_EMEA/short_EMEA/test.de-en.de
2021-01-24 03:24:07 | INFO | fairseq.data.data_utils | loaded 320 examples from: ../../../data-bin/custom_EMEA/short_EMEA/test.de-en.en
2021-01-24 03:24:07 | INFO | fairseq.tasks.translation | ../../../data-bin/custom_EMEA/short_EMEA test de-en 320 examples
2021-01-24 03:24:07 | INFO | fairseq_cli.generate | loading model(s) from ../checkpoints/EMEA_15/checkpoint_best.pt
S-122	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-122	Place the vials on a flat clean surface .
H-122	-0.369113028049469	Place the vials on a level surface .
D-122	-0.369113028049469	Place the vials on a level surface .
P-122	-1.6455 -0.1528 -0.1176 -0.0839 -0.1364 -0.5835 -0.5927 -0.0586 -0.1677 -0.1523
S-195	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-195	- Use within three hours after reconstitution .
H-195	-0.3972530961036682	- Use within 3 hours after reconstitution .
D-195	-0.3972530961036682	- Use within 3 hours after reconstitution .
P-195	-0.1158 -1.2028 -0.1091 -0.9377 -0.1504 -0.8695 -0.1597 -0.0805 -0.1801 -0.1670
S-95	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-95	- Use within three hours after reconstitution .
H-95	-0.3972530961036682	- Use within 3 hours after reconstitution .
D-95	-0.3972530961036682	- Use within 3 hours after reconstitution .
P-95	-0.1158 -1.2028 -0.1091 -0.9377 -0.1504 -0.8695 -0.1597 -0.0805 -0.1801 -0.1670
S-120	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-120	- Use within three hours after reconstitution .
H-120	-0.3972530961036682	- Use within 3 hours after reconstitution .
D-120	-0.3972530961036682	- Use within 3 hours after reconstitution .
P-120	-0.1158 -1.2028 -0.1091 -0.9377 -0.1504 -0.8695 -0.1597 -0.0805 -0.1801 -0.1670
S-170	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-170	- Use within three hours after reconstitution .
H-170	-0.3972530961036682	- Use within 3 hours after reconstitution .
D-170	-0.3972530961036682	- Use within 3 hours after reconstitution .
P-170	-0.1158 -1.2028 -0.1091 -0.9377 -0.1504 -0.8695 -0.1597 -0.0805 -0.1801 -0.1670
S-145	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-145	- Use within three hours after reconstitution .
H-145	-0.3972530961036682	- Use within 3 hours after reconstitution .
D-145	-0.3972530961036682	- Use within 3 hours after reconstitution .
P-145	-0.1158 -1.2028 -0.1091 -0.9377 -0.1504 -0.8695 -0.1597 -0.0805 -0.1801 -0.1670
S-221	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-221	- Use within three hours after reconstitution .
H-221	-0.3972530961036682	- Use within 3 hours after reconstitution .
D-221	-0.3972530961036682	- Use within 3 hours after reconstitution .
P-221	-0.1158 -1.2028 -0.1091 -0.9377 -0.1504 -0.8695 -0.1597 -0.0805 -0.1801 -0.1670
S-72	Welchen Nutzen hat Advate in diesen Studien gezeigt ?
T-72	What benefit has Advate shown during the studies ?
H-72	-0.22139158844947815	What benefit has Advate shown during the studies ?
D-72	-0.22139158844947815	What benefit has Advate shown during the studies ?
P-72	-0.1744 -0.1191 -0.1800 -0.5454 -0.1468 -0.0855 -0.1688 -0.6347 -0.0604 -0.1586 -0.1615
S-97	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-97	Place the vials on a flat clean surface .
H-97	-0.369113028049469	Place the vials on a level surface .
D-97	-0.369113028049469	Place the vials on a level surface .
P-97	-1.6455 -0.1528 -0.1176 -0.0839 -0.1364 -0.5835 -0.5927 -0.0586 -0.1677 -0.1523
S-134	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-134	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-134	-0.32118311524391174	Diarrhoea Abdominal pain Nausea Vomiting
D-134	-0.32118311524391174	Diarrhoea Abdominal pain Nausea Vomiting
P-134	-0.9825 -0.0286 -0.0911 -0.0177 -2.0923 -0.0133 -0.0526 -0.0910 -0.6220 -0.0502 -0.1179 -0.0327 -0.1004 -0.2044
S-147	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-147	Place the vials on a flat clean surface .
H-147	-0.369113028049469	Place the vials on a level surface .
D-147	-0.369113028049469	Place the vials on a level surface .
P-147	-1.6455 -0.1528 -0.1176 -0.0839 -0.1364 -0.5835 -0.5927 -0.0586 -0.1677 -0.1523
S-197	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-197	Place the vials on a flat clean surface .
H-197	-0.369113028049469	Place the vials on a level surface .
D-197	-0.369113028049469	Place the vials on a level surface .
P-197	-1.6455 -0.1528 -0.1176 -0.0839 -0.1364 -0.5835 -0.5927 -0.0586 -0.1677 -0.1523
S-311	Tablette mit veränderter Wirkstofffreisetzung
T-311	Oral use Oral use Oral use Oral use Oral use Oral use
H-311	-1.0054092407226562	Changed drug release tablet
D-311	-1.0054092407226562	Changed drug release tablet
P-311	-4.6930 -0.1446 -0.2273 -1.7441 -0.7085 -0.1702 -0.0928 -0.2627
S-223	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-223	Place the vials on a flat clean surface .
H-223	-0.369113028049469	Place the vials on a level surface .
D-223	-0.369113028049469	Place the vials on a level surface .
P-223	-1.6455 -0.1528 -0.1176 -0.0839 -0.1364 -0.5835 -0.5927 -0.0586 -0.1677 -0.1523
S-2	Reproduction is authorised provided the source is acknowledged .
T-2	Reproduction is authorised provided the source is acknowledged .
H-2	-0.11459031701087952	Reproduction is authorised provided the source is acknowledged .
D-2	-0.11459031701087952	Reproduction is authorised provided the source is acknowledged .
P-2	-0.1049 -0.1495 -0.1500 -0.1383 -0.1054 -0.0480 -0.1397 -0.0460 -0.1466 -0.0371 -0.1557 -0.1540
S-302	Reproduction is authorised provided the source is acknowledged .
T-302	Reproduction is authorised provided the source is acknowledged .
H-302	-0.11459031701087952	Reproduction is authorised provided the source is acknowledged .
D-302	-0.11459031701087952	Reproduction is authorised provided the source is acknowledged .
P-302	-0.1049 -0.1495 -0.1500 -0.1383 -0.1054 -0.0480 -0.1397 -0.0460 -0.1466 -0.0371 -0.1557 -0.1540
S-172	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-172	Place the vials on a flat clean surface .
H-172	-0.369113028049469	Place the vials on a level surface .
D-172	-0.369113028049469	Place the vials on a level surface .
P-172	-1.6455 -0.1528 -0.1176 -0.0839 -0.1364 -0.5835 -0.5927 -0.0586 -0.1677 -0.1523
S-310	Tablette mit veränderter Wirkstofffreisetzung
T-310	Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet
H-310	-1.0054092407226562	Changed drug release tablet
D-310	-1.0054092407226562	Changed drug release tablet
P-310	-4.6930 -0.1446 -0.2273 -1.7441 -0.7085 -0.1702 -0.0928 -0.2627
S-109	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-109	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-109	-0.32118311524391174	Diarrhoea Abdominal pain Nausea Vomiting
D-109	-0.32118311524391174	Diarrhoea Abdominal pain Nausea Vomiting
P-109	-0.9825 -0.0286 -0.0911 -0.0177 -2.0923 -0.0133 -0.0526 -0.0910 -0.6220 -0.0502 -0.1179 -0.0327 -0.1004 -0.2044
S-96	- Nach Rekonstitution nicht mehr kühlen .
T-96	- Do not refrigerate the preparation after reconstitution .
H-96	-0.21831580996513367	- Do not refrigerate after reconstitution .
D-96	-0.21831580996513367	- Do not refrigerate after reconstitution .
P-96	-0.1226 -0.0874 -0.1212 -0.9430 -0.3293 -0.0788 -0.1335 -0.2556 -0.1278 -0.1122 -0.1488 -0.1596
S-146	- Nach Rekonstitution nicht mehr kühlen .
T-146	- Do not refrigerate the preparation after reconstitution .
H-146	-0.21831580996513367	- Do not refrigerate after reconstitution .
D-146	-0.21831580996513367	- Do not refrigerate after reconstitution .
P-146	-0.1226 -0.0874 -0.1212 -0.9430 -0.3293 -0.0788 -0.1335 -0.2556 -0.1278 -0.1122 -0.1488 -0.1596
S-284	Im Zweifelsfall fragen Sie Ihren Arzt .
T-284	If you are unsure about this , ask your doctor .
H-284	-0.3451792299747467	Ask your doctor if in any doubt .
D-284	-0.3451792299747467	Ask your doctor if in any doubt .
P-284	-0.2425 -0.1243 -0.1363 -0.1021 -0.1253 -1.5312 -0.8232 -0.0527 -0.1592 -0.1552
S-121	- Nach Rekonstitution nicht mehr kühlen .
T-121	- Do not refrigerate the preparation after reconstitution .
H-121	-0.21831580996513367	- Do not refrigerate after reconstitution .
D-121	-0.21831580996513367	- Do not refrigerate after reconstitution .
P-121	-0.1226 -0.0874 -0.1212 -0.9430 -0.3293 -0.0788 -0.1335 -0.2556 -0.1278 -0.1122 -0.1488 -0.1596
S-24	Vitamin D einmal pro Tag wurde nicht untersucht .
T-24	The equivalence of intake of 5600 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 800 IU has not been studied .
H-24	-0.2989002466201782	Vitamin D given once a day has not been studied .
D-24	-0.2989002466201782	Vitamin D given once a day has not been studied .
P-24	-1.1750 -0.0700 -0.1162 -0.8490 -0.1625 -0.2512 -0.1120 -0.1201 -0.1411 -0.1270 -0.4650 -0.1432 -0.1533
S-300	Wofür sollte Advexin angewendet werden ?
T-300	What was Advexin expected to be used for ?
H-300	-0.29651913046836853	What should Advexin be used for ?
D-300	-0.29651913046836853	What should Advexin be used for ?
P-300	-0.4272 -0.9553 -0.5315 -0.1410 -0.1521 -0.1169 -0.1196 -0.1114 -0.2463 -0.1639
S-196	- Nach Rekonstitution nicht mehr kühlen .
T-196	- Do not refrigerate the preparation after reconstitution .
H-196	-0.21831580996513367	- Do not refrigerate after reconstitution .
D-196	-0.21831580996513367	- Do not refrigerate after reconstitution .
P-196	-0.1226 -0.0874 -0.1212 -0.9430 -0.3293 -0.0788 -0.1335 -0.2556 -0.1278 -0.1122 -0.1488 -0.1596
S-171	- Nach Rekonstitution nicht mehr kühlen .
T-171	- Do not refrigerate the preparation after reconstitution .
H-171	-0.21831580996513367	- Do not refrigerate after reconstitution .
D-171	-0.21831580996513367	- Do not refrigerate after reconstitution .
P-171	-0.1226 -0.0874 -0.1212 -0.9430 -0.3293 -0.0788 -0.1335 -0.2556 -0.1278 -0.1122 -0.1488 -0.1596
S-222	- Nach Rekonstitution nicht mehr kühlen .
T-222	- Do not refrigerate the preparation after reconstitution .
H-222	-0.21831580996513367	- Do not refrigerate after reconstitution .
D-222	-0.21831580996513367	- Do not refrigerate after reconstitution .
P-222	-0.1226 -0.0874 -0.1212 -0.9430 -0.3293 -0.0788 -0.1335 -0.2556 -0.1278 -0.1122 -0.1488 -0.1596
S-89	Verletzung , Vergiftung und durch Eingriffe
T-89	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-89	-0.7586025595664978	Injury , poisoning and procedures
D-89	-0.7586025595664978	Injury , poisoning and procedures
P-89	-0.6879 -0.3138 -0.1586 -0.6383 -0.1786 -0.2260 -3.5803 -0.2854
S-100	Nur klare , farblose Lösungen verwenden .
T-100	Only a clear and colourless solution should be used .
H-100	-0.1872936338186264	Use only clear , colourless solutions .
D-100	-0.1872936338186264	Use only clear , colourless solutions .
P-100	-0.1917 -0.4479 -0.1536 -0.2603 -0.1728 -0.0957 -0.0766 -0.1503 -0.1622 -0.1617
S-73	Die Genehmigung wurde am 2. März 2009 verlängert .
T-73	The marketing authorisation was renewed on 2 March 2009.
H-73	-0.2972169816493988	The marketing authorisation was renewed on 2 March 2009 .
D-73	-0.2972169816493988	The marketing authorisation was renewed on 2 March 2009 .
P-73	-0.1652 -1.5188 -0.0336 -0.0787 -0.1615 -0.3160 -0.1119 -0.1397 -0.2583 -0.4689 -0.1597 -0.1542
S-150	Nur klare , farblose Lösungen verwenden .
T-150	Only a clear and colourless solution should be used .
H-150	-0.1872936338186264	Use only clear , colourless solutions .
D-150	-0.1872936338186264	Use only clear , colourless solutions .
P-150	-0.1917 -0.4479 -0.1536 -0.2603 -0.1728 -0.0957 -0.0766 -0.1503 -0.1622 -0.1617
S-307	In der zweiten Studie wurden ähnliche Ergebnisse beobachtet .
T-307	Similar results were seen in the second study .
H-307	-0.35009515285491943	Similar results were observed in the second study .
D-307	-0.35009515285491943	Similar results were observed in the second study .
P-307	-1.2106 -0.0878 -1.1101 -0.1454 -0.3492 -0.1573 -0.1576 -0.1541 -0.1764 -0.1492 -0.1534
S-303	Was waren die wesentlichen Bedenken des CHMP ?
T-303	What were the main concerns of the CHMP ?
H-303	-0.25287190079689026	What were the main concerns of the CHMP ?
D-303	-0.25287190079689026	What were the main concerns of the CHMP ?
P-303	-0.0991 -0.3472 -0.1466 -0.8612 -0.1107 -0.4254 -0.2218 -0.1172 -0.0439 -0.2487 -0.1598
S-125	Nur klare , farblose Lösungen verwenden .
T-125	Only a clear and colourless solution should be used .
H-125	-0.1872936338186264	Use only clear , colourless solutions .
D-125	-0.1872936338186264	Use only clear , colourless solutions .
P-125	-0.1917 -0.4479 -0.1536 -0.2603 -0.1728 -0.0957 -0.0766 -0.1503 -0.1622 -0.1617
S-280	- Dieses Arzneimittel wurde Ihnen verschrieben .
T-280	- This medicine has been prescribed for you .
H-280	-0.15416187047958374	- This medicine has been prescribed for you .
D-280	-0.15416187047958374	- This medicine has been prescribed for you .
P-280	-0.1240 -0.1555 -0.1370 -0.0973 -0.1136 -0.0414 -0.0762 -0.4910 -0.1433 -0.1533 -0.1633
S-175	Nur klare , farblose Lösungen verwenden .
T-175	Only a clear and colourless solution should be used .
H-175	-0.1872936338186264	Use only clear , colourless solutions .
D-175	-0.1872936338186264	Use only clear , colourless solutions .
P-175	-0.1917 -0.4479 -0.1536 -0.2603 -0.1728 -0.0957 -0.0766 -0.1503 -0.1622 -0.1617
S-200	Nur klare , farblose Lösungen verwenden .
T-200	Only a clear and colourless solution should be used .
H-200	-0.1872936338186264	Use only clear , colourless solutions .
D-200	-0.1872936338186264	Use only clear , colourless solutions .
P-200	-0.1917 -0.4479 -0.1536 -0.2603 -0.1728 -0.0957 -0.0766 -0.1503 -0.1622 -0.1617
S-226	Nur klare , farblose Lösungen verwenden .
T-226	Only a clear and colourless solution should be used .
H-226	-0.1872936338186264	Use only clear , colourless solutions .
D-226	-0.1872936338186264	Use only clear , colourless solutions .
P-226	-0.1917 -0.4479 -0.1536 -0.2603 -0.1728 -0.0957 -0.0766 -0.1503 -0.1622 -0.1617
S-281	Es darf nicht an Dritte weitergegeben werden .
T-281	Es darf nicht an Dritte weitergegeben werden . It may harm them , even
H-281	-0.4441674053668976	It must not be passed on to third parties .
D-281	-0.4441674053668976	It must not be passed on to third parties .
P-281	-0.2453 -1.0207 -0.1342 -0.1285 -1.7682 -0.1683 -0.1303 -0.7960 -0.1838 -0.1533 -0.1574
S-87	Gelegentlich Gelegentlich Gelegentlich
T-87	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-87	-0.3543805778026581	Uncommon Uncommon Uncommon
D-87	-0.3543805778026581	Uncommon Uncommon Uncommon
P-87	-1.2281 -0.0611 -0.0791 -0.1536 -0.0873 -0.1410 -0.7305
S-83	Erkrankungen des Gastrointestinaltrakts
T-83	5 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-83	-0.13177861273288727	Gastrointestinal disorders
D-83	-0.13177861273288727	Gastrointestinal disorders
P-83	-0.2121 -0.0826 -0.0574 -0.1280 -0.0615 -0.1757 -0.1077 -0.2292
S-288	Arzneimittel für Kinder unzugänglich aufbewahren .
T-288	Keep out of the reach and sight of children .
H-288	-0.10706489533185959	Keep out of the reach and sight of children .
D-288	-0.10706489533185959	Keep out of the reach and sight of children .
P-288	-0.0539 -0.1111 -0.1463 -0.1340 -0.0583 -0.1211 -0.0274 -0.1458 -0.0749 -0.1448 -0.1601
S-198	Das Transfersystem nicht aus der Verpackung
T-198	Do not remove the device from the package .
H-198	-0.5643500089645386	Do not take the transfer system out of the package
D-198	-0.5643500089645386	Do not take the transfer system out of the package
P-198	-2.8781 -0.1820 -0.8858 -0.1564 -0.0925 -0.2313 -0.1492 -0.1433 -0.1461 -1.0978 -0.2452
S-224	Das Transfersystem nicht aus der Verpackung
T-224	Do not remove the device from the package .
H-224	-0.5643500089645386	Do not take the transfer system out of the package
D-224	-0.5643500089645386	Do not take the transfer system out of the package
P-224	-2.8781 -0.1820 -0.8858 -0.1564 -0.0925 -0.2313 -0.1492 -0.1433 -0.1461 -1.0978 -0.2452
S-250	Vor der Anwendung Gebrauchsinformation lesen .
T-250	Vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-250	-0.39479756355285645	Read the leaflet before use .
D-250	-0.39479756355285645	Read the leaflet before use .
P-250	-0.0532 -0.7481 -1.8441 -0.0620 -0.0872 -0.1988 -0.2411 -0.1623 -0.1564
S-173	Das Transfersystem nicht aus der Verpackung
T-173	Do not remove the device from the package .
H-173	-0.5643500089645386	Do not take the transfer system out of the package
D-173	-0.5643500089645386	Do not take the transfer system out of the package
P-173	-2.8781 -0.1820 -0.8858 -0.1564 -0.0925 -0.2313 -0.1492 -0.1433 -0.1461 -1.0978 -0.2452
S-148	Das Transfersystem nicht aus der Verpackung
T-148	Do not remove the device from the package .
H-148	-0.5643500089645386	Do not take the transfer system out of the package
D-148	-0.5643500089645386	Do not take the transfer system out of the package
P-148	-2.8781 -0.1820 -0.8858 -0.1564 -0.0925 -0.2313 -0.1492 -0.1433 -0.1461 -1.0978 -0.2452
S-123	Das Transfersystem nicht aus der Verpackung
T-123	Do not remove the device from the package .
H-123	-0.5643500089645386	Do not take the transfer system out of the package
D-123	-0.5643500089645386	Do not take the transfer system out of the package
P-123	-2.8781 -0.1820 -0.8858 -0.1564 -0.0925 -0.2313 -0.1492 -0.1433 -0.1461 -1.0978 -0.2452
S-290	Diese Maßnahme hilft die Umwelt zu schützen .
T-290	These measures will help to protect the environment .
H-290	-0.13261418044567108	These measures will help to protect the environment .
D-290	-0.13261418044567108	These measures will help to protect the environment .
P-290	-0.1387 -0.1114 -0.1513 -0.1215 -0.1548 -0.1196 -0.1413 -0.0876 -0.1459 -0.1538
S-98	Das Transfersystem nicht aus der Verpackung
T-98	Do not remove the device from the package .
H-98	-0.5643500089645386	Do not take the transfer system out of the package
D-98	-0.5643500089645386	Do not take the transfer system out of the package
P-98	-2.8781 -0.1820 -0.8858 -0.1564 -0.0925 -0.2313 -0.1492 -0.1433 -0.1461 -1.0978 -0.2452
S-275	vor der Anwendung Gebrauchsinformation lesen .
T-275	vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-275	-0.5279569625854492	read the leaflet before use .
D-275	-0.5279569625854492	read the leaflet before use .
P-275	-0.3507 -1.6505 -1.7313 -0.0529 -0.0874 -0.2322 -0.2782 -0.2081 -0.1602
S-285	Sie sollten über frühe Anzeichen einer solchen
T-285	Sie sollten über frühe Anzeichen einer solchen These symptoms can constitute an early
H-285	-0.6667912006378174	You should be aware of early signs of such
D-285	-0.6667912006378174	You should be aware of early signs of such
P-285	-0.4932 -0.1522 -0.8674 -2.6250 -0.1567 -0.2196 -0.1263 -0.1706 -0.6456 -1.2114
S-111	0,85 0,43 0,43 0,43
T-111	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-111	-0.30342769622802734	0.85 0,43 0,43 0,43
D-111	-0.30342769622802734	0.85 0,43 0,43 0,43
P-111	-0.3577 -0.2380 -0.9868 -0.1202 -0.2726 -0.1062 -0.2810 -0.1095 -0.2589
S-136	0,85 0,43 0,43 0,43
T-136	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-136	-0.30342769622802734	0.85 0,43 0,43 0,43
D-136	-0.30342769622802734	0.85 0,43 0,43 0,43
P-136	-0.3577 -0.2380 -0.9868 -0.1202 -0.2726 -0.1062 -0.2810 -0.1095 -0.2589
S-161	0,85 0,43 0,43 0,43
T-161	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-161	-0.30342769622802734	0.85 0,43 0,43 0,43
D-161	-0.30342769622802734	0.85 0,43 0,43 0,43
P-161	-0.3577 -0.2380 -0.9868 -0.1202 -0.2726 -0.1062 -0.2810 -0.1095 -0.2589
S-186	0,85 0,43 0,43 0,43
T-186	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-186	-0.30342769622802734	0.85 0,43 0,43 0,43
D-186	-0.30342769622802734	0.85 0,43 0,43 0,43
P-186	-0.3577 -0.2380 -0.9868 -0.1202 -0.2726 -0.1062 -0.2810 -0.1095 -0.2589
S-212	0,85 0,43 0,43 0,43
T-212	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-212	-0.30342769622802734	0.85 0,43 0,43 0,43
D-212	-0.30342769622802734	0.85 0,43 0,43 0,43
P-212	-0.3577 -0.2380 -0.9868 -0.1202 -0.2726 -0.1062 -0.2810 -0.1095 -0.2589
S-209	Infektionen und parasitäre Erkrankungen
T-209	( % patients<<unk>> a Infections and infestations Blood and lymphatic system disorders
H-209	-0.287131667137146	Infections and parasitic disorders
D-209	-0.287131667137146	Infections and parasitic disorders
P-209	-0.1290 -0.1962 -0.1487 -0.1886 -0.0797 -0.1653 -1.3620 -0.1053 -0.2095
S-272	Für Kinder unzugänglich aufbewahren .
T-272	Keep out of the reach and sight of children .
H-272	-0.11318521946668625	Keep out of the reach and sight of children .
D-272	-0.11318521946668625	Keep out of the reach and sight of children .
P-272	-0.1158 -0.1060 -0.1460 -0.1373 -0.0443 -0.1223 -0.0213 -0.1469 -0.0989 -0.1450 -0.1611
S-256	Für Kinder unzugänglich aufbewahren .
T-256	Keep out of the reach and sight of children .
H-256	-0.11318521946668625	Keep out of the reach and sight of children .
D-256	-0.11318521946668625	Keep out of the reach and sight of children .
P-256	-0.1158 -0.1060 -0.1460 -0.1373 -0.0443 -0.1223 -0.0213 -0.1469 -0.0989 -0.1450 -0.1611
S-314	Erwachsene und Jugendliche ab 12 Jahren :
T-314	Adults and adolescents 12 years of age and over :
H-314	-0.40012213587760925	Adults and adolescents aged 12 years and over :
D-314	-0.40012213587760925	Adults and adolescents aged 12 years and over :
P-314	-0.2002 -0.7146 -0.1783 -0.2232 -0.0563 -0.0443 -1.5260 -0.1781 -1.0985 -0.3328 -0.3303 -0.1537 -0.1653
S-264	Für Kinder unzugänglich aufbewahren .
T-264	Keep out of the reach and sight of children .
H-264	-0.11318521946668625	Keep out of the reach and sight of children .
D-264	-0.11318521946668625	Keep out of the reach and sight of children .
P-264	-0.1158 -0.1060 -0.1460 -0.1373 -0.0443 -0.1223 -0.0213 -0.1469 -0.0989 -0.1450 -0.1611
S-239	Für Kinder unzugänglich aufbewahren .
T-239	Keep out of the reach and sight of children .
H-239	-0.11318521946668625	Keep out of the reach and sight of children .
D-239	-0.11318521946668625	Keep out of the reach and sight of children .
P-239	-0.1158 -0.1060 -0.1460 -0.1373 -0.0443 -0.1223 -0.0213 -0.1469 -0.0989 -0.1450 -0.1611
S-247	Für Kinder unzugänglich aufbewahren .
T-247	Keep out of the reach and sight of children .
H-247	-0.11318521946668625	Keep out of the reach and sight of children .
D-247	-0.11318521946668625	Keep out of the reach and sight of children .
P-247	-0.1158 -0.1060 -0.1460 -0.1373 -0.0443 -0.1223 -0.0213 -0.1469 -0.0989 -0.1450 -0.1611
S-231	Für Kinder unzugänglich aufbewahren .
T-231	Keep out of the reach and sight of children .
H-231	-0.11318521946668625	Keep out of the reach and sight of children .
D-231	-0.11318521946668625	Keep out of the reach and sight of children .
P-231	-0.1158 -0.1060 -0.1460 -0.1373 -0.0443 -0.1223 -0.0213 -0.1469 -0.0989 -0.1450 -0.1611
S-90	Pharmakotherapeutische Gruppe :
T-90	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-90	-0.213103786110878	Pharmacotherapeutic group :
D-90	-0.213103786110878	Pharmacotherapeutic group :
P-90	-0.7930 -0.0464 -0.0844 -0.0773 -0.2347 -0.1313 -0.2083 -0.1570 -0.1855
S-216	Pharmakotherapeutische Gruppe :
T-216	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-216	-0.213103786110878	Pharmacotherapeutic group :
D-216	-0.213103786110878	Pharmacotherapeutic group :
P-216	-0.7930 -0.0464 -0.0844 -0.0773 -0.2347 -0.1313 -0.2083 -0.1570 -0.1855
S-190	Pharmakotherapeutische Gruppe :
T-190	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-190	-0.213103786110878	Pharmacotherapeutic group :
D-190	-0.213103786110878	Pharmacotherapeutic group :
P-190	-0.7930 -0.0464 -0.0844 -0.0773 -0.2347 -0.1313 -0.2083 -0.1570 -0.1855
S-165	Pharmakotherapeutische Gruppe :
T-165	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-165	-0.213103786110878	Pharmacotherapeutic group :
D-165	-0.213103786110878	Pharmacotherapeutic group :
P-165	-0.7930 -0.0464 -0.0844 -0.0773 -0.2347 -0.1313 -0.2083 -0.1570 -0.1855
S-140	Pharmakotherapeutische Gruppe :
T-140	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-140	-0.213103786110878	Pharmacotherapeutic group :
D-140	-0.213103786110878	Pharmacotherapeutic group :
P-140	-0.7930 -0.0464 -0.0844 -0.0773 -0.2347 -0.1313 -0.2083 -0.1570 -0.1855
S-115	Pharmakotherapeutische Gruppe :
T-115	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-115	-0.213103786110878	Pharmacotherapeutic group :
D-115	-0.213103786110878	Pharmacotherapeutic group :
P-115	-0.7930 -0.0464 -0.0844 -0.0773 -0.2347 -0.1313 -0.2083 -0.1570 -0.1855
S-86	0,43 0,43 0,43
T-86	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-86	-0.2844952344894409	0.43 0.43 0.43 0.43
D-86	-0.2844952344894409	0.43 0.43 0.43 0.43
P-86	-0.7845 -0.1563 -0.3801 -0.1060 -0.2770 -0.1015 -0.4729 -0.0908 -0.1914
S-58	ADROVANCE
T-58	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-58	-0.5843124389648438	ADROVANCE
D-58	-0.5843124389648438	ADROVANCE
P-58	-1.6115 -0.0886 -0.1459 -0.1028 -0.0820 -1.4751
S-57	Alendronat
T-57	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-57	-0.1864616721868515	Alendronate
D-57	-0.1864616721868515	Alendronate
P-57	-0.2854 -0.1402 -0.1246 -0.1291 -0.2530
S-141	PK-Parameter
T-141	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-141	-0.6444199085235596	PK parameters
D-141	-0.6444199085235596	PK parameters
P-141	-1.9304 -0.1731 -0.4111 -1.0374 -0.1305 -0.1840
S-40	ADROVANCE
T-40	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-40	-0.5843124389648438	ADROVANCE
D-40	-0.5843124389648438	ADROVANCE
P-40	-1.6115 -0.0886 -0.1459 -0.1028 -0.0820 -1.4751
S-56	ADROVANCE
T-56	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-56	-0.5843124389648438	ADROVANCE
D-56	-0.5843124389648438	ADROVANCE
P-56	-1.6115 -0.0886 -0.1459 -0.1028 -0.0820 -1.4751
S-38	Alendronat
T-38	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-38	-0.1864616721868515	Alendronate
D-38	-0.1864616721868515	Alendronate
P-38	-0.2854 -0.1402 -0.1246 -0.1291 -0.2530
S-91	PK-Parameter
T-91	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-91	-0.6444199085235596	PK parameters
D-91	-0.6444199085235596	PK parameters
P-91	-1.9304 -0.1731 -0.4111 -1.0374 -0.1305 -0.1840
S-37	ADROVANCE
T-37	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-37	-0.5843124389648438	ADROVANCE
D-37	-0.5843124389648438	ADROVANCE
P-37	-1.6115 -0.0886 -0.1459 -0.1028 -0.0820 -1.4751
S-166	PK-Parameter
T-166	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-166	-0.6444199085235596	PK parameters
D-166	-0.6444199085235596	PK parameters
P-166	-1.9304 -0.1731 -0.4111 -1.0374 -0.1305 -0.1840
S-191	PK-Parameter
T-191	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-191	-0.6444199085235596	PK parameters
D-191	-0.6444199085235596	PK parameters
P-191	-1.9304 -0.1731 -0.4111 -1.0374 -0.1305 -0.1840
S-116	PK-Parameter
T-116	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-116	-0.6444199085235596	PK parameters
D-116	-0.6444199085235596	PK parameters
P-116	-1.9304 -0.1731 -0.4111 -1.0374 -0.1305 -0.1840
S-39	ADROVANCE
T-39	Your doctor has prescribed ADROVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency .
H-39	-0.5843124389648438	ADROVANCE
D-39	-0.5843124389648438	ADROVANCE
P-39	-1.6115 -0.0886 -0.1459 -0.1028 -0.0820 -1.4751
S-217	PK-Parameter
T-217	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-217	-0.6444199085235596	PK parameters
D-217	-0.6444199085235596	PK parameters
P-217	-1.9304 -0.1731 -0.4111 -1.0374 -0.1305 -0.1840
S-309	2,5 mg / 120 mg
T-309	2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg
H-309	-0.1371433287858963	2.5 mg / 120 mg
D-309	-0.1371433287858963	2.5 mg / 120 mg
P-309	-0.2681 -0.0534 -0.1773 -0.0859 -0.0476 -0.1904
S-60	ADROVANCE
T-60	47 5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-60	-0.5843124389648438	ADROVANCE
D-60	-0.5843124389648438	ADROVANCE
P-60	-1.6115 -0.0886 -0.1459 -0.1028 -0.0820 -1.4751
S-45	ADROVANCE
T-45	5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-45	-0.5843124389648438	ADROVANCE
D-45	-0.5843124389648438	ADROVANCE
P-45	-1.6115 -0.0886 -0.1459 -0.1028 -0.0820 -1.4751
S-211	2 1 1 1
T-211	2 1 1 1 2 2 1 1 3 1
H-211	-1.4396216869354248	2 1 1
D-211	-1.4396216869354248	2 1 1
P-211	-3.0292 -0.2893 -0.3066 -2.1334
S-135	2 1 1 1
T-135	2 1 1 1 2 2 1 1 3 1
H-135	-1.4396216869354248	2 1 1
D-135	-1.4396216869354248	2 1 1
P-135	-3.0292 -0.2893 -0.3066 -2.1334
S-110	2 1 1 1
T-110	2 1 1 1 2 2 1 1 3 1
H-110	-1.4396216869354248	2 1 1
D-110	-1.4396216869354248	2 1 1
P-110	-3.0292 -0.2893 -0.3066 -2.1334
S-185	2 1 1 1
T-185	2 1 1 1 2 2 1 1 3 1
H-185	-1.4396216869354248	2 1 1
D-185	-1.4396216869354248	2 1 1
P-185	-3.0292 -0.2893 -0.3066 -2.1334
S-16	32 % ) .
T-16	32 % , respectively ) , through week 15.
H-16	-0.25813302397727966	32 % ) .
D-16	-0.25813302397727966	32 % ) .
P-16	-0.5787 -0.1409 -0.1494 -0.2603 -0.1614
S-48	Informieren Sie
T-48	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-48	-1.685178518295288	Inform your doctor or pharmacist
D-48	-1.685178518295288	Inform your doctor or pharmacist
P-48	-5.6206 -0.1403 -2.4284 -0.3610 -0.9521 -0.4065 -0.1996 -3.3730
S-160	2 1 1 1
T-160	2 1 1 1 2 2 1 1 3 1
H-160	-1.4396216869354248	2 1 1
D-160	-1.4396216869354248	2 1 1
P-160	-3.0292 -0.2893 -0.3066 -2.1334
S-313	14 Tabletten
T-313	2 tablets 4 tablets 7 tablets 10 tablets 14 tablets 20 tablets
H-313	-0.3393750786781311	14 tablets
D-313	-0.3393750786781311	14 tablets
P-313	-0.6141 -0.3540 -0.1890 -0.2004
S-63	Informieren Sie
T-63	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-63	-1.685178518295288	Inform your doctor or pharmacist
D-63	-1.685178518295288	Inform your doctor or pharmacist
P-63	-5.6206 -0.1403 -2.4284 -0.3610 -0.9521 -0.4065 -0.1996 -3.3730
S-84	Verabreichungsort
T-84	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-84	-0.8886417150497437	Administration site
D-84	-0.8886417150497437	Administration site
P-84	-2.1646 -0.3160 -0.1854
S-29	32 % ) .
T-29	32 % , respectively ) , through week 15.
H-29	-0.25813302397727966	32 % ) .
D-29	-0.25813302397727966	32 % ) .
P-29	-0.5787 -0.1409 -0.1494 -0.2603 -0.1614
S-62	Gelegentlich
T-62	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-62	-1.123504877090454	Occasional
D-62	-1.123504877090454	Occasional
P-62	-4.6439 -0.2075 -0.1341 -0.3969 -0.2352
S-61	Häufig :
T-61	The following terms are used to describe how often side effects have been reported :
H-61	-1.377729892730713	Frequent :
D-61	-1.377729892730713	Frequent :
P-61	-4.9245 -0.0260 -1.5289 -0.1123 -0.2970
S-47	Gelegentlich
T-47	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-47	-1.123504877090454	Occasional
D-47	-1.123504877090454	Occasional
P-47	-4.6439 -0.2075 -0.1341 -0.3969 -0.2352
S-85	1 1 1
T-85	2 1 1 1 2 2 1 1 3 1
H-85	-2.9904263019561768	1 1 1 1 1 1
D-85	-2.9904263019561768	1 1 1 1 1 1
P-85	-11.7753 -2.0604 -0.7708 -0.9951 -1.8933 -1.9896 -1.4485
S-51	Tel . :
T-51	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-51	-1.1290408372879028	Tel : <unk> 353 ( 0 ) 2 00 00 00 00
D-51	-1.1290408372879028	Tel : <unk> 353 ( 0 ) 2 00 00 00 00
P-51	-0.1284 -0.9451 -0.0942 -2.0207 -1.0499 -0.1968 -0.0886 -0.1138 -1.8117 -2.9021 -0.9742 -0.4635 -0.4676 -4.5500
S-66	Tel . :
T-66	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-66	-1.1290408372879028	Tel : <unk> 353 ( 0 ) 2 00 00 00 00
D-66	-1.1290408372879028	Tel : <unk> 353 ( 0 ) 2 00 00 00 00
P-66	-0.1284 -0.9451 -0.0942 -2.0207 -1.0499 -0.1968 -0.0886 -0.1138 -1.8117 -2.9021 -0.9742 -0.4635 -0.4676 -4.5500
S-55	Tel : +
T-55	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-55	-0.9150452613830566	Tel : + 353 ( 0 ) 2 00 00 00 00
D-55	-0.9150452613830566	Tel : + 353 ( 0 ) 2 00 00 00 00
P-55	-0.0444 -0.1471 -0.1403 -2.7823 -0.6878 -0.6846 -0.0223 -0.1491 -1.7023 -2.8239 -0.4492 -0.5466 -0.8535 -1.7772
S-70	Tel : +
T-70	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-70	-0.9150452613830566	Tel : + 353 ( 0 ) 2 00 00 00 00
D-70	-0.9150452613830566	Tel : + 353 ( 0 ) 2 00 00 00 00
P-70	-0.0444 -0.1471 -0.1403 -2.7823 -0.6878 -0.6846 -0.0223 -0.1491 -1.7023 -2.8239 -0.4492 -0.5466 -0.8535 -1.7772
S-46	Häufig :
T-46	The following terms are used to describe how often side effects have been reported :
H-46	-1.377729892730713	Frequent :
D-46	-1.377729892730713	Frequent :
P-46	-4.9245 -0.0260 -1.5289 -0.1123 -0.2970
S-68	Tel :
T-68	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-68	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
D-68	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
P-68	-0.0966 -0.1335 -0.0063 -0.8584 -0.6456 -0.1035 -0.1012 -0.1214 -1.4885 -1.4659 -0.2569 -0.4016 -2.9634 -0.0342 -0.8063
S-69	Tel :
T-69	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-69	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
D-69	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
P-69	-0.0966 -0.1335 -0.0063 -0.8584 -0.6456 -0.1035 -0.1012 -0.1214 -1.4885 -1.4659 -0.2569 -0.4016 -2.9634 -0.0342 -0.8063
S-53	Tel :
T-53	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-53	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
D-53	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
P-53	-0.0966 -0.1335 -0.0063 -0.8584 -0.6456 -0.1035 -0.1012 -0.1214 -1.4885 -1.4659 -0.2569 -0.4016 -2.9634 -0.0342 -0.8063
S-54	Tel :
T-54	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-54	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
D-54	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
P-54	-0.0966 -0.1335 -0.0063 -0.8584 -0.6456 -0.1035 -0.1012 -0.1214 -1.4885 -1.4659 -0.2569 -0.4016 -2.9634 -0.0342 -0.8063
S-52	Tel :
T-52	Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-52	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
D-52	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
P-52	-0.0966 -0.1335 -0.0063 -0.8584 -0.6456 -0.1035 -0.1012 -0.1214 -1.4885 -1.4659 -0.2569 -0.4016 -2.9634 -0.0342 -0.8063
S-67	Tel :
T-67	50 Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-67	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
D-67	-0.6322218179702759	Tel : <unk> 353 ( 0 ) 2 00 00 00 lp
P-67	-0.0966 -0.1335 -0.0063 -0.8584 -0.6456 -0.1035 -0.1012 -0.1214 -1.4885 -1.4659 -0.2569 -0.4016 -2.9634 -0.0342 -0.8063
S-82	0,43
T-82	Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-82	-1.140629529953003	0.43 kg
D-82	-1.140629529953003	0.43 kg
P-82	-2.0176 -0.1391 -2.1499 -0.2560
S-50	Die
T-50	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-50	-1.173812747001648	The study also looked at the effect of ACOMPLIA on mood disorders , such as mood swings , mood changes and mood swings .
D-50	-1.173812747001648	The study also looked at the effect of ACOMPLIA on mood disorders , such as mood swings , mood changes and mood swings .
P-50	-1.2300 -4.8977 -2.6520 -0.9634 -0.1168 -2.4011 -1.0354 -0.2980 -3.4699 -0.0544 -0.0121 -0.0257 -0.0042 -0.1959 -2.4533 -2.6401 -0.1123 -1.2329 -3.8046 -0.1356 -1.0294 -0.3004 -0.2937 -0.3793 -2.0370 -0.9615 -1.0328 -0.6020 -0.7230 -0.2477 -2.0656 -0.1544
S-43	(
T-43	40 3 ) Do not lie down stay fully upright ( sitting , standing or walking ) for at least 30 minutes after swallowing the tablet .
H-43	-1.5087201595306396	( CNN ) -- A Florida man has been charged with attempted murder in the shooting death of an elderly woman who was riding a bike when she was struck by a car .
D-43	-1.5087201595306396	( CNN ) -- A Florida man has been charged with attempted murder in the shooting death of an elderly woman who was riding a bike when she was struck by a car .
P-43	-2.0579 -4.2672 -0.1802 -0.1509 -2.2131 -3.7359 -1.3917 -2.3315 -0.4001 -0.8757 -0.1854 -3.4108 -0.4200 -1.5280 -0.3532 -1.9440 -0.5485 -0.1471 -3.6601 -0.7159 -0.6176 -1.6872 -0.7077 -2.9760 -0.7373 -2.9369 -2.5365 -1.5955 -1.8609 -2.1445 -0.4542 -0.3793 -2.1071 -1.3947 -0.1527
S-317	2
T-317	2 a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke .
H-317	-2.4967565536499023	2 .
D-317	-2.4967565536499023	2 .
P-317	-5.6053 -1.6762 -0.2087
S-44	(
T-44	4 ) Do not take ADROVANCE at bedtime or before getting up for the day .
H-44	-1.5087201595306396	( CNN ) -- A Florida man has been charged with attempted murder in the shooting death of an elderly woman who was riding a bike when she was struck by a car .
D-44	-1.5087201595306396	( CNN ) -- A Florida man has been charged with attempted murder in the shooting death of an elderly woman who was riding a bike when she was struck by a car .
P-44	-2.0579 -4.2672 -0.1802 -0.1509 -2.2131 -3.7359 -1.3917 -2.3315 -0.4001 -0.8757 -0.1854 -3.4108 -0.4200 -1.5280 -0.3532 -1.9440 -0.5485 -0.1471 -3.6601 -0.7159 -0.6176 -1.6872 -0.7077 -2.9760 -0.7373 -2.9369 -2.5365 -1.5955 -1.8609 -2.1445 -0.4542 -0.3793 -2.1071 -1.3947 -0.1527
S-65	Die
T-65	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-65	-1.173812747001648	The study also looked at the effect of ACOMPLIA on mood disorders , such as mood swings , mood changes and mood swings .
D-65	-1.173812747001648	The study also looked at the effect of ACOMPLIA on mood disorders , such as mood swings , mood changes and mood swings .
P-65	-1.2300 -4.8977 -2.6520 -0.9634 -0.1168 -2.4011 -1.0354 -0.2980 -3.4699 -0.0544 -0.0121 -0.0257 -0.0042 -0.1959 -2.4533 -2.6401 -0.1123 -1.2329 -3.8046 -0.1356 -1.0294 -0.3004 -0.2937 -0.3793 -2.0370 -0.9615 -1.0328 -0.6020 -0.7230 -0.2477 -2.0656 -0.1544
S-64	Das
T-64	The expiry date refers to the last day of that month .
H-64	-0.9091166257858276	This is Money has a regularly updated guide to the best offers carefully chosen by its expert writers our guide to the top interest groups
D-64	-0.9091166257858276	This is Money has a regularly updated guide to the best offers carefully chosen by its expert writers our guide to the top interest groups
P-64	-5.8756 -1.2176 -1.5437 -1.4387 -1.4877 -1.0319 -0.1405 -1.5964 -0.0725 -0.1018 -0.3505 -0.1380 -0.0063 -0.0721 -0.7183 -0.2015 -0.5450 -0.0684 -0.0725 -0.6695 -0.2524 -0.2289 -0.2469 -1.3515 -3.5832 -0.6258
S-35	2.
T-35	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-35	-1.6230756044387817	2 ) How to store ABILIFY ABILIFY
D-35	-1.6230756044387817	2 ) How to store ABILIFY ABILIFY
P-35	-6.1999 -2.4532 -4.7025 -0.3208 -2.2982 -2.5783 -0.0154 -0.0869 -0.1058 -0.0744 -3.5392 -0.0965 -0.0738 -0.0721 -0.0516 -3.3008
S-36	2.
T-36	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-36	-1.6230756044387817	2 ) How to store ABILIFY ABILIFY
D-36	-1.6230756044387817	2 ) How to store ABILIFY ABILIFY
P-36	-6.1999 -2.4532 -4.7025 -0.3208 -2.2982 -2.5783 -0.0154 -0.0869 -0.1058 -0.0744 -3.5392 -0.0965 -0.0738 -0.0721 -0.0516 -3.3008
S-41	Sie
T-41	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-41	-1.2922643423080444	You should check with your doctor or pharmacist before you start to take this medicine .
D-41	-1.2922643423080444	You should check with your doctor or pharmacist before you start to take this medicine .
P-41	-2.3720 -3.7979 -3.1879 -1.4019 -0.0682 -0.9792 -2.9795 -0.1809 -0.1468 -1.2575 -1.1968 -0.2034 -1.3512 -0.1452 -2.6763 -0.2288 -0.9271 -0.1601
S-59	Sie
T-59	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-59	-1.2922643423080444	You should check with your doctor or pharmacist before you start to take this medicine .
D-59	-1.2922643423080444	You should check with your doctor or pharmacist before you start to take this medicine .
P-59	-2.3720 -3.7979 -3.1879 -1.4019 -0.0682 -0.9792 -2.9795 -0.1809 -0.1468 -1.2575 -1.1968 -0.2034 -1.3512 -0.1452 -2.6763 -0.2288 -0.9271 -0.1601
S-42	(
T-42	2 ) After getting up for the day and before taking any food , drink , or other medicine , swallow your ADROVANCE tablet with a full glass of water only ( not mineral water ) ( not less than 200 ml or 7 fl . oz . ) . Do not take with mineral water ( still or sparkling ) . Do not take with coffee or tea . Do not take with juice or milk .
H-42	-1.5087201595306396	( CNN ) -- A Florida man has been charged with attempted murder in the shooting death of an elderly woman who was riding a bike when she was struck by a car .
D-42	-1.5087201595306396	( CNN ) -- A Florida man has been charged with attempted murder in the shooting death of an elderly woman who was riding a bike when she was struck by a car .
P-42	-2.0579 -4.2672 -0.1802 -0.1509 -2.2131 -3.7359 -1.3917 -2.3315 -0.4001 -0.8757 -0.1854 -3.4108 -0.4200 -1.5280 -0.3532 -1.9440 -0.5485 -0.1471 -3.6601 -0.7159 -0.6176 -1.6872 -0.7077 -2.9760 -0.7373 -2.9369 -2.5365 -1.5955 -1.8609 -2.1445 -0.4542 -0.3793 -2.1071 -1.3947 -0.1527
S-49	Das
T-49	The expiry date refers to the last day of that month .
H-49	-0.9091166257858276	This is Money has a regularly updated guide to the best offers carefully chosen by its expert writers our guide to the top interest groups
D-49	-0.9091166257858276	This is Money has a regularly updated guide to the best offers carefully chosen by its expert writers our guide to the top interest groups
P-49	-5.8756 -1.2176 -1.5437 -1.4387 -1.4877 -1.0319 -0.1405 -1.5964 -0.0725 -0.1018 -0.3505 -0.1380 -0.0063 -0.0721 -0.7183 -0.2015 -0.5450 -0.0684 -0.0725 -0.6695 -0.2524 -0.2289 -0.2469 -1.3515 -3.5832 -0.6258
S-108	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-108	Animal reproduction studies have not been conducted with factor VIII .
H-108	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
D-108	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
P-108	-1.8287 -0.0657 -0.1469 -0.7916 -0.0253 -0.4545 -0.0992 -0.1126 -0.2123 -0.4617 -0.5408 -0.1816 -0.0751 -0.1466 -0.1550
S-77	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-77	More extensive haemarthrosis , muscle bleeding or haematoma .
H-77	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
D-77	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
P-77	-0.8166 -0.2083 -0.0697 -0.1509 -0.4584 -0.0862 -0.0333 -0.2152 -0.1495 -0.7436 -0.5605 -0.0607 -0.0255 -0.1591 -1.1881 -0.0919 -0.2554 -0.0300 -0.0802 -0.0497 -0.1542 -0.1547
S-204	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-204	More extensive haemarthrosis , muscle bleeding or haematoma .
H-204	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
D-204	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
P-204	-0.8166 -0.2083 -0.0697 -0.1509 -0.4584 -0.0862 -0.0333 -0.2152 -0.1495 -0.7436 -0.5605 -0.0607 -0.0255 -0.1591 -1.1881 -0.0919 -0.2554 -0.0300 -0.0802 -0.0497 -0.1542 -0.1547
S-133	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-133	Animal reproduction studies have not been conducted with factor VIII .
H-133	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
D-133	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
P-133	-1.8287 -0.0657 -0.1469 -0.7916 -0.0253 -0.4545 -0.0992 -0.1126 -0.2123 -0.4617 -0.5408 -0.1816 -0.0751 -0.1466 -0.1550
S-158	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-158	Animal reproduction studies have not been conducted with factor VIII .
H-158	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
D-158	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
P-158	-1.8287 -0.0657 -0.1469 -0.7916 -0.0253 -0.4545 -0.0992 -0.1126 -0.2123 -0.4617 -0.5408 -0.1816 -0.0751 -0.1466 -0.1550
S-183	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-183	Animal reproduction studies have not been conducted with factor VIII .
H-183	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
D-183	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
P-183	-1.8287 -0.0657 -0.1469 -0.7916 -0.0253 -0.4545 -0.0992 -0.1126 -0.2123 -0.4617 -0.5408 -0.1816 -0.0751 -0.1466 -0.1550
S-74	1 Durchstechflasche + 1 Durchstechflasche + Gerät zur Rekonstitution
T-74	1 vial + 1 vial + reconstitution device
H-74	-0.33599162101745605	1 vial + 1 vial + reconstitution device
D-74	-0.33599162101745605	1 vial + 1 vial + reconstitution device
P-74	-0.1806 -0.0634 -0.0801 -0.1208 -0.1494 -0.0762 -0.1235 -0.1165 -0.6160 -0.0967 -2.2301 -0.1785
S-293	eská republika Baxter Czech spol.s.r.o .
T-293	eská republika Baxter Czech spol . s. r. o.
H-293	-0.23683175444602966	eská republika Baxter Czech spol. s. r. o .
D-293	-0.23683175444602966	eská republika Baxter Czech spol. s. r. o .
P-293	-0.1114 -0.1881 -0.0706 -0.0504 -0.0901 -0.1092 -0.1559 -0.1593 -0.0591 -0.0809 -0.0756 -1.2922 -0.3502 -0.1245 -0.7745 -0.1682 -0.1660
S-208	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-208	Animal reproduction studies have not been conducted with factor VIII .
H-208	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
D-208	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
P-208	-1.8287 -0.0657 -0.1469 -0.7916 -0.0253 -0.4545 -0.0992 -0.1126 -0.2123 -0.4617 -0.5408 -0.1816 -0.0751 -0.1466 -0.1550
S-104	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-104	More extensive haemarthrosis , muscle bleeding or haematoma .
H-104	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
D-104	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
P-104	-0.8166 -0.2083 -0.0697 -0.1509 -0.4584 -0.0862 -0.0333 -0.2152 -0.1495 -0.7436 -0.5605 -0.0607 -0.0255 -0.1591 -1.1881 -0.0919 -0.2554 -0.0300 -0.0802 -0.0497 -0.1542 -0.1547
S-129	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-129	More extensive haemarthrosis , muscle bleeding or haematoma .
H-129	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
D-129	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
P-129	-0.8166 -0.2083 -0.0697 -0.1509 -0.4584 -0.0862 -0.0333 -0.2152 -0.1495 -0.7436 -0.5605 -0.0607 -0.0255 -0.1591 -1.1881 -0.0919 -0.2554 -0.0300 -0.0802 -0.0497 -0.1542 -0.1547
S-154	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-154	More extensive haemarthrosis , muscle bleeding or haematoma .
H-154	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
D-154	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
P-154	-0.8166 -0.2083 -0.0697 -0.1509 -0.4584 -0.0862 -0.0333 -0.2152 -0.1495 -0.7436 -0.5605 -0.0607 -0.0255 -0.1591 -1.1881 -0.0919 -0.2554 -0.0300 -0.0802 -0.0497 -0.1542 -0.1547
S-179	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-179	More extensive haemarthrosis , muscle bleeding or haematoma .
H-179	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
D-179	-0.2609899938106537	More pronounced joint haemorrhage , muscle haemorrhage , or haematoma .
P-179	-0.8166 -0.2083 -0.0697 -0.1509 -0.4584 -0.0862 -0.0333 -0.2152 -0.1495 -0.7436 -0.5605 -0.0607 -0.0255 -0.1591 -1.1881 -0.0919 -0.2554 -0.0300 -0.0802 -0.0497 -0.1542 -0.1547
S-81	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-81	Animal reproduction studies have not been conducted with factor VIII .
H-81	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
D-81	-0.3531688153743744	Animal reproduction studies have not been performed with factor VIII .
P-81	-1.8287 -0.0657 -0.1469 -0.7916 -0.0253 -0.4545 -0.0992 -0.1126 -0.2123 -0.4617 -0.5408 -0.1816 -0.0751 -0.1466 -0.1550
S-144	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-144	For administration the use of a luer-lock syringe is required .
H-144	-0.2625987231731415	A Luer-Lock syringe is required for administration .
D-144	-0.2625987231731415	A Luer-Lock syringe is required for administration .
P-144	-0.6707 -0.2305 -0.3185 -0.2995 -0.8643 -0.0865 -0.2231 -0.0247 -0.0181 -0.1546 -0.2361 -0.3809 -0.1207 -0.1585 -0.1523
S-220	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-220	For administration the use of a luer-lock syringe is required .
H-220	-0.2625987231731415	A Luer-Lock syringe is required for administration .
D-220	-0.2625987231731415	A Luer-Lock syringe is required for administration .
P-220	-0.6707 -0.2305 -0.3185 -0.2995 -0.8643 -0.0865 -0.2231 -0.0247 -0.0181 -0.1546 -0.2361 -0.3809 -0.1207 -0.1585 -0.1523
S-93	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-93	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-93	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
D-93	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
P-93	-0.1422 -0.4014 -0.2416 -0.1900 -0.1443 -0.9896 -0.0624 -0.0842 -0.1324 -0.4894 -0.2106 -0.1385 -0.0935 -0.1539 -0.1666 -0.1552
S-169	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-169	For administration the use of a luer-lock syringe is required .
H-169	-0.2625987231731415	A Luer-Lock syringe is required for administration .
D-169	-0.2625987231731415	A Luer-Lock syringe is required for administration .
P-169	-0.6707 -0.2305 -0.3185 -0.2995 -0.8643 -0.0865 -0.2231 -0.0247 -0.0181 -0.1546 -0.2361 -0.3809 -0.1207 -0.1585 -0.1523
S-143	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-143	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-143	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
D-143	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
P-143	-0.1422 -0.4014 -0.2416 -0.1900 -0.1443 -0.9896 -0.0624 -0.0842 -0.1324 -0.4894 -0.2106 -0.1385 -0.0935 -0.1539 -0.1666 -0.1552
S-119	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-119	For administration the use of a luer-lock syringe is required .
H-119	-0.2625987231731415	A Luer-Lock syringe is required for administration .
D-119	-0.2625987231731415	A Luer-Lock syringe is required for administration .
P-119	-0.6707 -0.2305 -0.3185 -0.2995 -0.8643 -0.0865 -0.2231 -0.0247 -0.0181 -0.1546 -0.2361 -0.3809 -0.1207 -0.1585 -0.1523
S-94	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-94	For administration the use of a luer-lock syringe is required .
H-94	-0.2625987231731415	A Luer-Lock syringe is required for administration .
D-94	-0.2625987231731415	A Luer-Lock syringe is required for administration .
P-94	-0.6707 -0.2305 -0.3185 -0.2995 -0.8643 -0.0865 -0.2231 -0.0247 -0.0181 -0.1546 -0.2361 -0.3809 -0.1207 -0.1585 -0.1523
S-301	Li-Fraumeni-Krebs kann in vielen Teilen des Körpers auftreten .
T-301	People who have this mutation are more likely to develop cancer .
H-301	-0.3642676770687103	Li-Fraumeni cancer can occur in many parts of the body .
D-301	-0.3642676770687103	Li-Fraumeni cancer can occur in many parts of the body .
P-301	-1.7642 -0.0943 -0.5778 -0.0454 -0.2051 -0.8367 -0.6370 -0.2973 -0.1418 -0.3169 -0.2014 -0.1421 -0.1518 -0.0960 -0.1620 -0.1587
S-228	Name und Anschrift des Herstellers des Wirkstoffs biologischen Ursprungs
T-228	Name and address of the manufacturer of the biological active substance
H-228	-0.2648419737815857	Name and address of the manufacturer of the biological active substance
D-228	-0.2648419737815857	Name and address of the manufacturer of the biological active substance
P-228	-0.3271 -0.1298 -0.2039 -0.1449 -0.3924 -0.3013 -0.1442 -0.1441 -0.9087 -0.1848 -0.2619 -0.0758 -0.2240
S-130	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-130	Method of administration ADVATE should be administered via the intravenous route .
H-130	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
D-130	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
P-130	-1.8525 -0.0184 -0.0419 -0.1525 -0.2238 -0.1613 -0.1779 -0.0842 -0.0863 -1.1629 -0.1329 -0.8563 -0.0845 -0.1313 -0.0786 -0.0794 -0.1156 -0.1602 -0.1555
S-194	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-194	For administration the use of a luer-lock syringe is required .
H-194	-0.2625987231731415	A Luer-Lock syringe is required for administration .
D-194	-0.2625987231731415	A Luer-Lock syringe is required for administration .
P-194	-0.6707 -0.2305 -0.3185 -0.2995 -0.8643 -0.0865 -0.2231 -0.0247 -0.0181 -0.1546 -0.2361 -0.3809 -0.1207 -0.1585 -0.1523
S-17	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-17	Total body BMD also increased significantly .
H-17	-0.3988189995288849	The BMD of the total skeleton was also significantly increased .
D-17	-0.3988189995288849	The BMD of the total skeleton was also significantly increased .
P-17	-1.0472 -0.2596 -0.1098 -0.1814 -0.1413 -0.4227 -1.3791 -1.0511 -0.0562 -0.6558 -0.1209 -0.1792 -0.0840 -0.1449 -0.1490
S-118	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-118	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-118	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
D-118	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
P-118	-0.1422 -0.4014 -0.2416 -0.1900 -0.1443 -0.9896 -0.0624 -0.0842 -0.1324 -0.4894 -0.2106 -0.1385 -0.0935 -0.1539 -0.1666 -0.1552
S-155	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-155	Method of administration ADVATE should be administered via the intravenous route .
H-155	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
D-155	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
P-155	-1.8525 -0.0184 -0.0419 -0.1525 -0.2238 -0.1613 -0.1779 -0.0842 -0.0863 -1.1629 -0.1329 -0.8563 -0.0845 -0.1313 -0.0786 -0.0794 -0.1156 -0.1602 -0.1555
S-25	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-25	14 Excipients This medicinal product contains lactose and sucrose .
H-25	-0.10743748396635056	Excipients This medicinal product contains lactose and sucrose .
D-25	-0.10743748396635056	Excipients This medicinal product contains lactose and sucrose .
P-25	-0.3246 -0.0404 -0.1078 -0.1086 -0.1340 -0.0749 -0.1530 -0.0687 -0.0740 -0.1000 -0.0178 -0.1008 -0.1347 -0.0584 -0.0638 -0.0655 -0.1523 -0.1545
S-5	Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-5	EU/ 1/ 08/ 447/ 001 EU/ 1/ 08/ 447/ 002 EU/ 1/ 08/ 447/ 003 EU/ 1/ 08/ 447/ 004
H-5	-0.21166500449180603	Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium )
D-5	-0.21166500449180603	Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium )
P-5	-0.1001 -0.1894 -0.1811 -0.1655 -0.2558 -0.1253 -0.1770 -0.1379 -0.1463 -0.1690 -0.1744 -0.1061 -0.0752 -0.1523 -1.3122 -0.1839 -0.2046 -0.1511 -0.2640 -0.1229 -0.1924 -0.1177 -0.1214 -0.1646 -0.1705 -0.1036 -0.0502 -0.1414 -0.6824
S-205	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-205	Method of administration ADVATE should be administered via the intravenous route .
H-205	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
D-205	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
P-205	-1.8525 -0.0184 -0.0419 -0.1525 -0.2238 -0.1613 -0.1779 -0.0842 -0.0863 -1.1629 -0.1329 -0.8563 -0.0845 -0.1313 -0.0786 -0.0794 -0.1156 -0.1602 -0.1555
S-180	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-180	Method of administration ADVATE should be administered via the intravenous route .
H-180	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
D-180	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
P-180	-1.8525 -0.0184 -0.0419 -0.1525 -0.2238 -0.1613 -0.1779 -0.0842 -0.0863 -1.1629 -0.1329 -0.8563 -0.0845 -0.1313 -0.0786 -0.0794 -0.1156 -0.1602 -0.1555
S-193	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-193	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-193	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
D-193	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
P-193	-0.1422 -0.4014 -0.2416 -0.1900 -0.1443 -0.9896 -0.0624 -0.0842 -0.1324 -0.4894 -0.2106 -0.1385 -0.0935 -0.1539 -0.1666 -0.1552
S-105	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-105	Method of administration ADVATE should be administered via the intravenous route .
H-105	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
D-105	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
P-105	-1.8525 -0.0184 -0.0419 -0.1525 -0.2238 -0.1613 -0.1779 -0.0842 -0.0863 -1.1629 -0.1329 -0.8563 -0.0845 -0.1313 -0.0786 -0.0794 -0.1156 -0.1602 -0.1555
S-219	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-219	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-219	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
D-219	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
P-219	-0.1422 -0.4014 -0.2416 -0.1900 -0.1443 -0.9896 -0.0624 -0.0842 -0.1324 -0.4894 -0.2106 -0.1385 -0.0935 -0.1539 -0.1666 -0.1552
S-78	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-78	Method of administration ADVATE should be administered via the intravenous route .
H-78	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
D-78	-0.30294400453567505	Method of administration ADVATE should be administered intravenously .
P-78	-1.8525 -0.0184 -0.0419 -0.1525 -0.2238 -0.1613 -0.1779 -0.0842 -0.0863 -1.1629 -0.1329 -0.8563 -0.0845 -0.1313 -0.0786 -0.0794 -0.1156 -0.1602 -0.1555
S-168	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-168	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-168	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
D-168	-0.23722916841506958	For storage conditions of the reconstituted product , see section 6.3 .
P-168	-0.1422 -0.4014 -0.2416 -0.1900 -0.1443 -0.9896 -0.0624 -0.0842 -0.1324 -0.4894 -0.2106 -0.1385 -0.0935 -0.1539 -0.1666 -0.1552
S-12	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-12	4 Excipients This medicinal product contains lactose and sucrose .
H-12	-0.10743748396635056	Excipients This medicinal product contains lactose and sucrose .
D-12	-0.10743748396635056	Excipients This medicinal product contains lactose and sucrose .
P-12	-0.3246 -0.0404 -0.1078 -0.1086 -0.1340 -0.0749 -0.1530 -0.0687 -0.0740 -0.1000 -0.0178 -0.1008 -0.1347 -0.0584 -0.0638 -0.0655 -0.1523 -0.1545
S-30	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-30	Total body BMD also increased significantly .
H-30	-0.3988189995288849	The BMD of the total skeleton was also significantly increased .
D-30	-0.3988189995288849	The BMD of the total skeleton was also significantly increased .
P-30	-1.0472 -0.2596 -0.1098 -0.1814 -0.1413 -0.4227 -1.3791 -1.0511 -0.0562 -0.6558 -0.1209 -0.1792 -0.0840 -0.1449 -0.1490
S-292	H-1123 Budapest Tel . : <unk> 361 202 19 80
T-292	H-1123 Budapest Tel . : <<unk>> 361 202 19 80
H-292	-0.12083019316196442	H-1123 Budapest Tel . : <unk> 361 202 19 80
D-292	-0.12083019316196442	H-1123 Budapest Tel . : <unk> 361 202 19 80
P-292	-0.2107 -0.1303 -0.1185 -0.0400 -0.1601 -0.0601 -0.1608 -0.1387 -0.0278 -0.1337 -0.0615 -0.1157 -0.1332 -0.1160 -0.1288 -0.1972
S-99	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-99	Do not remove the blue cap from the BAXJECT II device .
H-99	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
D-99	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
P-99	-0.1896 -0.1372 -0.0781 -0.1587 -0.1580 -1.2840 -0.0998 -0.1170 -0.7750 -0.3340 -0.1350 -0.2772 -0.0967 -0.1173 -0.1108 -0.1475 -0.1559
S-149	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-149	Do not remove the blue cap from the BAXJECT II device .
H-149	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
D-149	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
P-149	-0.1896 -0.1372 -0.0781 -0.1587 -0.1580 -1.2840 -0.0998 -0.1170 -0.7750 -0.3340 -0.1350 -0.2772 -0.0967 -0.1173 -0.1108 -0.1475 -0.1559
S-33	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-33	Further hydroxylation occurs prior to elimination .
H-33	-0.20303839445114136	Further hydroxylation occurs prior to excretion .
D-33	-0.20303839445114136	Further hydroxylation occurs prior to excretion .
P-33	-0.5107 -0.0815 -0.1049 -0.1545 -0.1597 -0.3560 -0.0813 -0.5421 -0.1480 -0.1936 -0.0718 -0.1293 -0.1562 -0.1530
S-20	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-20	Further hydroxylation occurs prior to elimination .
H-20	-0.20303839445114136	Further hydroxylation occurs prior to excretion .
D-20	-0.20303839445114136	Further hydroxylation occurs prior to excretion .
P-20	-0.5107 -0.0815 -0.1049 -0.1545 -0.1597 -0.3560 -0.0813 -0.5421 -0.1480 -0.1936 -0.0718 -0.1293 -0.1562 -0.1530
S-124	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-124	Do not remove the blue cap from the BAXJECT II device .
H-124	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
D-124	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
P-124	-0.1896 -0.1372 -0.0781 -0.1587 -0.1580 -1.2840 -0.0998 -0.1170 -0.7750 -0.3340 -0.1350 -0.2772 -0.0967 -0.1173 -0.1108 -0.1475 -0.1559
S-8	Die empfohlene Dosis beträgt eine Tablette einmal wöchentlich .
T-8	The recommended dose is one tablet once a week .
H-8	-0.24986808001995087	The recommended dose is one tablet once a week .
D-8	-0.24986808001995087	The recommended dose is one tablet once a week .
P-8	-0.1666 -0.0727 -0.0953 -0.1571 -0.2125 -0.1012 -0.0957 -0.8572 -0.8189 -0.1144 -0.1558 -0.1509
S-174	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-174	Do not remove the blue cap from the BAXJECT II device .
H-174	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
D-174	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
P-174	-0.1896 -0.1372 -0.0781 -0.1587 -0.1580 -1.2840 -0.0998 -0.1170 -0.7750 -0.3340 -0.1350 -0.2772 -0.0967 -0.1173 -0.1108 -0.1475 -0.1559
S-199	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-199	Do not remove the blue cap from the BAXJECT II device .
H-199	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
D-199	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
P-199	-0.1896 -0.1372 -0.0781 -0.1587 -0.1580 -1.2840 -0.0998 -0.1170 -0.7750 -0.3340 -0.1350 -0.2772 -0.0967 -0.1173 -0.1108 -0.1475 -0.1559
S-225	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-225	Do not remove the blue cap from the BAXJECT II device .
H-225	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
D-225	-0.25715556740760803	Do not remove the blue protective cap from the BAXJECT II .
P-225	-0.1896 -0.1372 -0.0781 -0.1587 -0.1580 -1.2840 -0.0998 -0.1170 -0.7750 -0.3340 -0.1350 -0.2772 -0.0967 -0.1173 -0.1108 -0.1475 -0.1559
S-286	Normalerweise wird die Ersatztherapie mit ADVATE lebenslang durchgeführt .
T-286	Usually , the replacement therapy with ADVATE is a life-long treatment .
H-286	-0.35430532693862915	Normally , the replacement therapy with ADVATE is lifelong .
D-286	-0.35430532693862915	Normally , the replacement therapy with ADVATE is lifelong .
P-286	-1.2533 -0.1239 -0.5080 -0.8467 -0.1548 -0.1369 -0.1246 -0.1093 -0.1644 -0.0881 -0.0865 -0.1668 -1.3050 -0.1053 -0.3426 -0.1525
S-305	Aerinaze enthält zwei arzneilich wirksame Bestandteile :
T-305	Aerinaze contains two active substances : desloratadine , an antihistamine , and pseudoephedrine , which is a nasal decongestant .
H-305	-0.18772324919700623	Aerinaze contains two active ingredients :
D-305	-0.18772324919700623	Aerinaze contains two active ingredients :
P-305	-0.1540 -0.1229 -0.1270 -0.1318 -0.1140 -0.2217 -0.1259 -0.3754 -0.3775 -0.1521 -0.1626
S-316	Aerinaze ist ebenfalls kontraindiziert bei Patienten mit :
T-316	Aerinaze is also contraindicated in patients with : narrow-angle glaucoma , urinary retention , cardiovascular diseases such as ischaemic heart disease , tachyarrhythmia and severe hypertension , hyperthyroidism ,
H-316	-0.17016631364822388	Aerinaze is also contraindicated in patients with :
D-316	-0.17016631364822388	Aerinaze is also contraindicated in patients with :
P-316	-0.1630 -0.1177 -0.1259 -0.1409 -0.0970 -0.1292 -0.0914 -0.1716 -0.0264 -0.3771 -0.1428 -0.4567 -0.1693 -0.1734
S-312	Blister ( PCTFE<unk> PVC<unk> Alu )
T-312	Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu )
H-312	-0.25798824429512024	Blister ( PCTFE/ PVC/ alu ) Blister ( PCTFE/ PVC/ alu )
D-312	-0.25798824429512024	Blister ( PCTFE/ PVC/ alu ) Blister ( PCTFE/ PVC/ alu )
P-312	-0.3102 -0.2311 -0.1470 -0.2708 -0.1358 -0.1530 -0.1186 -0.2723 -0.1384 -0.1446 -0.1653 -0.1740 -0.2184 -0.3227 -0.1478 -1.6077 -0.1456 -0.1936 -0.3385 -0.1335 -0.1481 -0.0983 -0.1938 -0.1227 -0.1310 -0.1630 -0.1932 -0.1002 -0.2516 -0.1348 -1.0918
S-107	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-107	4.5 Interaction with other medicinal products and other forms of interaction
H-107	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
D-107	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
P-107	-0.3595 -0.1321 -1.0752 -0.1265 -0.0895 -0.1199 -0.1008 -0.0860 -0.0551 -0.1152 -0.1428 -0.1957 -0.0389 -0.1506 -0.1159 -0.0716 -0.1607
S-157	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-157	4.5 Interaction with other medicinal products and other forms of interaction
H-157	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
D-157	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
P-157	-0.3595 -0.1321 -1.0752 -0.1265 -0.0895 -0.1199 -0.1008 -0.0860 -0.0551 -0.1152 -0.1428 -0.1957 -0.0389 -0.1506 -0.1159 -0.0716 -0.1607
S-80	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-80	4.5 Interaction with other medicinal products and other forms of interaction
H-80	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
D-80	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
P-80	-0.3595 -0.1321 -1.0752 -0.1265 -0.0895 -0.1199 -0.1008 -0.0860 -0.0551 -0.1152 -0.1428 -0.1957 -0.0389 -0.1506 -0.1159 -0.0716 -0.1607
S-132	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-132	4.5 Interaction with other medicinal products and other forms of interaction
H-132	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
D-132	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
P-132	-0.3595 -0.1321 -1.0752 -0.1265 -0.0895 -0.1199 -0.1008 -0.0860 -0.0551 -0.1152 -0.1428 -0.1957 -0.0389 -0.1506 -0.1159 -0.0716 -0.1607
S-206	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-206	The product contains traces of mouse and hamster proteins .
H-206	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
D-206	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
P-206	-3.3838 -0.1247 -0.4666 -0.2891 -0.1103 -0.1369 -0.3471 -0.0667 -0.1933 -0.0689 -0.0730 -0.1154 -0.0461 -0.1529 -0.1563
S-182	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-182	4.5 Interaction with other medicinal products and other forms of interaction
H-182	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
D-182	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
P-182	-0.3595 -0.1321 -1.0752 -0.1265 -0.0895 -0.1199 -0.1008 -0.0860 -0.0551 -0.1152 -0.1428 -0.1957 -0.0389 -0.1506 -0.1159 -0.0716 -0.1607
S-207	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-207	4.5 Interaction with other medicinal products and other forms of interaction
H-207	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
D-207	-0.18447230756282806	4.5 . Interaction with other medicinal products and other forms of interaction
P-207	-0.3595 -0.1321 -1.0752 -0.1265 -0.0895 -0.1199 -0.1008 -0.0860 -0.0551 -0.1152 -0.1428 -0.1957 -0.0389 -0.1506 -0.1159 -0.0716 -0.1607
S-289	Im Kühlschrank lagern ( 2<unk> C-8<unk> C ) .
T-289	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-289	-0.150381937623024	Store in a refrigerator ( 2<unk> C-8<unk> C ) .
D-289	-0.150381937623024	Store in a refrigerator ( 2<unk> C-8<unk> C ) .
P-289	-0.4520 -0.1637 -0.1849 -0.1452 -0.0508 -0.0732 -0.1262 -0.1275 -0.1238 -0.1331 -0.1616 -0.1897 -0.1467 -0.0493 -0.1226 -0.1488 -0.1516 -0.1561
S-23	Die Äquivalenz der Einnahme von 5.600 I.E.
T-23	ADROVANCE should not be taken at bedtime or before arising for the day .
H-23	-0.3167983889579773	The equivalent of taking 5,600 IU .
D-23	-0.3167983889579773	The equivalent of taking 5,600 IU .
P-23	-0.1881 -0.4676 -0.1437 -1.4674 -0.1717 -0.0729 -0.1133 -0.0710 -0.3181 -0.1542
S-296	Polska Baxter Poland Sp. z o.o. ul .
T-296	Polska Baxter Poland Sp . z o. o. ul .
H-296	-0.16319897770881653	Polska Baxter Poland Sp. z o.o. ul .
D-296	-0.16319897770881653	Polska Baxter Poland Sp. z o.o. ul .
P-296	-0.1683 -0.0949 -0.1554 -0.1488 -0.1536 -0.1629 -0.1258 -0.1468 -0.0852 -0.1672 -0.2835 -0.0492 -0.3801 -0.1625 -0.1639
S-156	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-156	The product contains traces of mouse and hamster proteins .
H-156	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
D-156	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
P-156	-3.3838 -0.1247 -0.4666 -0.2891 -0.1103 -0.1369 -0.3471 -0.0667 -0.1933 -0.0689 -0.0730 -0.1154 -0.0461 -0.1529 -0.1563
S-181	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-181	The product contains traces of mouse and hamster proteins .
H-181	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
D-181	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
P-181	-3.3838 -0.1247 -0.4666 -0.2891 -0.1103 -0.1369 -0.3471 -0.0667 -0.1933 -0.0689 -0.0730 -0.1154 -0.0461 -0.1529 -0.1563
S-131	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-131	The product contains traces of mouse and hamster proteins .
H-131	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
D-131	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
P-131	-3.3838 -0.1247 -0.4666 -0.2891 -0.1103 -0.1369 -0.3471 -0.0667 -0.1933 -0.0689 -0.0730 -0.1154 -0.0461 -0.1529 -0.1563
S-306	Welchen Nutzen hat Aerinaze in diesen Studien gezeigt ?
T-306	What benefit has Aerinaze shown during the studies ?
H-306	-0.15837863087654114	What benefit has Aerinaze shown during the studies ?
D-306	-0.15837863087654114	What benefit has Aerinaze shown during the studies ?
P-306	-0.1780 -0.0963 -0.1449 -0.1444 -0.1274 -0.1254 -0.1201 -0.1267 -0.0943 -0.1432 -0.5669 -0.0476 -0.1430 -0.1592
S-106	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-106	The product contains traces of mouse and hamster proteins .
H-106	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
D-106	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
P-106	-3.3838 -0.1247 -0.4666 -0.2891 -0.1103 -0.1369 -0.3471 -0.0667 -0.1933 -0.0689 -0.0730 -0.1154 -0.0461 -0.1529 -0.1563
S-79	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-79	The product contains traces of mouse and hamster proteins .
H-79	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
D-79	-0.38207438588142395	The product contains traces of mouse and hamster proteins .
P-79	-3.3838 -0.1247 -0.4666 -0.2891 -0.1103 -0.1369 -0.3471 -0.0667 -0.1933 -0.0689 -0.0730 -0.1154 -0.0461 -0.1529 -0.1563
S-31	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-31	Protein binding in human plasma is approximately 78 % .
H-31	-0.200214222073555	The protein binding in human plasma is approximately 78 % .
D-31	-0.200214222073555	The protein binding in human plasma is approximately 78 % .
P-31	-0.3552 -0.0552 -0.1463 -0.1033 -0.1469 -0.1353 -0.1199 -0.0864 -0.0940 -0.1389 -0.5060 -0.1042 -0.6845 -0.1753 -0.1519
S-18	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-18	Protein binding in human plasma is approximately 78 % .
H-18	-0.200214222073555	The protein binding in human plasma is approximately 78 % .
D-18	-0.200214222073555	The protein binding in human plasma is approximately 78 % .
P-18	-0.3552 -0.0552 -0.1463 -0.1033 -0.1469 -0.1353 -0.1199 -0.0864 -0.0940 -0.1389 -0.5060 -0.1042 -0.6845 -0.1753 -0.1519
S-10	Welchen Nutzen hat ADROVANCE in diesen Studien gezeigt ?
T-10	What benefit has ADROVANCE shown during the studies ?
H-10	-0.15671326220035553	What benefit has ADROVANCE shown during the studies ?
D-10	-0.15671326220035553	What benefit has ADROVANCE shown during the studies ?
P-10	-0.2582 -0.1277 -0.2006 -0.0255 -0.0743 -0.1482 -0.1080 -0.0985 -0.1156 -0.1471 -0.5425 -0.0427 -0.1421 -0.1629
S-3	Der Harnsäurespiegel im Blut wurde jeden Monat bestimmt .
T-3	Blood uric acid levels were measured every month .
H-3	-0.3715280592441559	The uric acid level in the blood was measured each month .
D-3	-0.3715280592441559	The uric acid level in the blood was measured each month .
P-3	-0.4639 -1.1350 -0.0872 -0.0676 -0.3287 -0.1750 -0.1677 -0.0600 -0.1587 -0.9775 -1.1965 -0.0893 -0.1440 -0.1502
S-151	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-151	02 March 2004 Date of last renewal :
H-151	-0.3331906795501709	02 March 2004 Date of last renewal :
D-151	-0.3331906795501709	02 March 2004 Date of last renewal :
P-151	-0.1836 -0.4746 -0.3842 -0.4165 -0.1479 -0.1323 -0.2347 -0.7643 -0.1486 -0.5931 -0.1854
S-101	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-101	02 March 2004 Date of last renewal :
H-101	-0.3331906795501709	02 March 2004 Date of last renewal :
D-101	-0.3331906795501709	02 March 2004 Date of last renewal :
P-101	-0.1836 -0.4746 -0.3842 -0.4165 -0.1479 -0.1323 -0.2347 -0.7643 -0.1486 -0.5931 -0.1854
S-176	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-176	02 March 2004 Date of last renewal :
H-176	-0.3331906795501709	02 March 2004 Date of last renewal :
D-176	-0.3331906795501709	02 March 2004 Date of last renewal :
P-176	-0.1836 -0.4746 -0.3842 -0.4165 -0.1479 -0.1323 -0.2347 -0.7643 -0.1486 -0.5931 -0.1854
S-102	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-102	The dose is determined using the following formula :
H-102	-0.2942979633808136	The required dose is calculated using the following formula :
D-102	-0.2942979633808136	The required dose is calculated using the following formula :
P-102	-0.4036 -0.5565 -0.0495 -0.9077 -0.1886 -0.1463 -0.5798 -0.1454 -0.1863 -0.0812 -0.1185 -0.1681
S-126	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-126	02 March 2004 Date of last renewal :
H-126	-0.3331906795501709	02 March 2004 Date of last renewal :
D-126	-0.3331906795501709	02 March 2004 Date of last renewal :
P-126	-0.1836 -0.4746 -0.3842 -0.4165 -0.1479 -0.1323 -0.2347 -0.7643 -0.1486 -0.5931 -0.1854
S-227	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-227	02 March 2004 Date of last renewal :
H-227	-0.3331906795501709	02 March 2004 Date of last renewal :
D-227	-0.3331906795501709	02 March 2004 Date of last renewal :
P-227	-0.1836 -0.4746 -0.3842 -0.4165 -0.1479 -0.1323 -0.2347 -0.7643 -0.1486 -0.5931 -0.1854
S-202	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-202	The dose is determined using the following formula :
H-202	-0.2942979633808136	The required dose is calculated using the following formula :
D-202	-0.2942979633808136	The required dose is calculated using the following formula :
P-202	-0.4036 -0.5565 -0.0495 -0.9077 -0.1886 -0.1463 -0.5798 -0.1454 -0.1863 -0.0812 -0.1185 -0.1681
S-177	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-177	The dose is determined using the following formula :
H-177	-0.2942979633808136	The required dose is calculated using the following formula :
D-177	-0.2942979633808136	The required dose is calculated using the following formula :
P-177	-0.4036 -0.5565 -0.0495 -0.9077 -0.1886 -0.1463 -0.5798 -0.1454 -0.1863 -0.0812 -0.1185 -0.1681
S-152	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-152	The dose is determined using the following formula :
H-152	-0.2942979633808136	The required dose is calculated using the following formula :
D-152	-0.2942979633808136	The required dose is calculated using the following formula :
P-152	-0.4036 -0.5565 -0.0495 -0.9077 -0.1886 -0.1463 -0.5798 -0.1454 -0.1863 -0.0812 -0.1185 -0.1681
S-75	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-75	The dose is determined using the following formula :
H-75	-0.2942979633808136	The required dose is calculated using the following formula :
D-75	-0.2942979633808136	The required dose is calculated using the following formula :
P-75	-0.4036 -0.5565 -0.0495 -0.9077 -0.1886 -0.1463 -0.5798 -0.1454 -0.1863 -0.0812 -0.1185 -0.1681
S-127	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-127	The dose is determined using the following formula :
H-127	-0.2942979633808136	The required dose is calculated using the following formula :
D-127	-0.2942979633808136	The required dose is calculated using the following formula :
P-127	-0.4036 -0.5565 -0.0495 -0.9077 -0.1886 -0.1463 -0.5798 -0.1454 -0.1863 -0.0812 -0.1185 -0.1681
S-13	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-13	4.5 Interaction with other medicinal products and other forms of interaction
H-13	-0.1187325194478035	4.5 Interaction with other medicinal products and other forms of interaction
D-13	-0.1187325194478035	4.5 Interaction with other medicinal products and other forms of interaction
P-13	-0.2376 -0.1280 -0.1087 -0.1035 -0.1185 -0.0910 -0.0854 -0.0557 -0.1211 -0.1408 -0.1792 -0.0364 -0.1526 -0.1117 -0.0732 -0.1563
S-291	Jede Pulver-Durchstechflasche enthält 250 I.E.
T-291	Each powder vial contains 250 IU octocog alfa .
H-291	-0.17783159017562866	Each vial contains 250 IU .
D-291	-0.17783159017562866	Each vial contains 250 IU .
P-291	-0.0439 -0.4058 -0.0441 -0.4454 -0.1088 -0.1253 -0.1015 -0.1719 -0.1538
S-26	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-26	4.5 Interaction with other medicinal products and other forms of interaction
H-26	-0.1187325194478035	4.5 Interaction with other medicinal products and other forms of interaction
D-26	-0.1187325194478035	4.5 Interaction with other medicinal products and other forms of interaction
P-26	-0.2376 -0.1280 -0.1087 -0.1035 -0.1185 -0.0910 -0.0854 -0.0557 -0.1211 -0.1408 -0.1792 -0.0364 -0.1526 -0.1117 -0.0732 -0.1563
S-27	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-27	No additional adverse reactions have been identified for ADROVANCE .
H-27	-0.3369150459766388	No other undesirable effects were observed for ADROVANCE .
D-27	-0.3369150459766388	No other undesirable effects were observed for ADROVANCE .
P-27	-0.4780 -0.3077 -1.7066 -0.2698 -0.0589 -0.0936 -0.5893 -0.8344 -0.2373 -0.1134 -0.0787 -0.1474 -0.0980 -0.0706 -0.1520 -0.1548
S-14	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-14	No additional adverse reactions have been identified for ADROVANCE .
H-14	-0.3369150459766388	No other undesirable effects were observed for ADROVANCE .
D-14	-0.3369150459766388	No other undesirable effects were observed for ADROVANCE .
P-14	-0.4780 -0.3077 -1.7066 -0.2698 -0.0589 -0.0936 -0.5893 -0.8344 -0.2373 -0.1134 -0.0787 -0.1474 -0.0980 -0.0706 -0.1520 -0.1548
S-318	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-318	4.5 Interaction with other medicinal products and other forms of interaction
H-318	-0.1187325194478035	4.5 Interaction with other medicinal products and other forms of interaction
D-318	-0.1187325194478035	4.5 Interaction with other medicinal products and other forms of interaction
P-318	-0.2376 -0.1280 -0.1087 -0.1035 -0.1185 -0.0910 -0.0854 -0.0557 -0.1211 -0.1408 -0.1792 -0.0364 -0.1526 -0.1117 -0.0732 -0.1563
S-15	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-15	Vitamin D3 is required for normal bone formation .
H-15	-0.23690667748451233	Vitamin D3 is required for normal bone formation .
D-15	-0.23690667748451233	Vitamin D3 is required for normal bone formation .
P-15	-0.1211 -0.0884 -0.1534 -0.1532 -0.1176 -1.0328 -0.1447 -0.0928 -0.0626 -0.5505 -0.1698 -0.1559
S-287	Häufige Nebenwirkungen Schwindel , Kopfschmerzen und Fieber
T-287	Common side effects dizziness , headache and fever .
H-287	-0.1906261295080185	Common side effects Dizziness , headache and fever
D-287	-0.1906261295080185	Common side effects Dizziness , headache and fever
P-287	-0.0353 -0.1299 -0.1427 -0.0920 -0.2166 -0.1936 -0.0518 -0.1624 -0.0882 -0.0449 -0.5455 -0.8729 -0.0445 -0.0615 -0.1775
S-28	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-28	Vitamin D3 is required for normal bone formation .
H-28	-0.23690667748451233	Vitamin D3 is required for normal bone formation .
D-28	-0.23690667748451233	Vitamin D3 is required for normal bone formation .
P-28	-0.1211 -0.0884 -0.1534 -0.1532 -0.1176 -1.0328 -0.1447 -0.0928 -0.0626 -0.5505 -0.1698 -0.1559
S-4	Welchen Nutzen hat Adenuric in diesen Studien gezeigt ?
T-4	What benefit has Adenuric shown during the studies ?
H-4	-0.15514634549617767	What benefit has Adenuric shown during the studies ?
D-4	-0.15514634549617767	What benefit has Adenuric shown during the studies ?
P-4	-0.1519 -0.0810 -0.1475 -0.1227 -0.1728 -0.0742 -0.1102 -0.0844 -0.1108 -0.6169 -0.0404 -0.1466 -0.1573
S-282	Was ist ADVATE und wofür wird es angewendet ?
T-282	What ADVATE is and what it is used for 2.
H-282	-0.12095166742801666	What ADVATE is and what it is used for 2.
D-282	-0.12095166742801666	What ADVATE is and what it is used for 2.
P-282	-0.1074 -0.1441 -0.1671 -0.0887 -0.1000 -0.1431 -0.1128 -0.1074 -0.1223 -0.1798 -0.1693 -0.1041 -0.0179 -0.1293
S-201	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-201	02 March 2004 Date of last renewal :
H-201	-0.3331906795501709	02 March 2004 Date of last renewal :
D-201	-0.3331906795501709	02 March 2004 Date of last renewal :
P-201	-0.1836 -0.4746 -0.3842 -0.4165 -0.1479 -0.1323 -0.2347 -0.7643 -0.1486 -0.5931 -0.1854
S-167	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-167	The product may not be returned to refrigerated storage again .
H-167	-0.4169763922691345	Do not store the product refrigerated .
D-167	-0.4169763922691345	Do not store the product refrigerated .
P-167	-0.4815 -0.1402 -0.1922 -0.2923 -0.0898 -2.6408 -0.1410 -0.0837 -0.1663 -0.2014 -0.1576
S-117	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-117	The product may not be returned to refrigerated storage again .
H-117	-0.4169763922691345	Do not store the product refrigerated .
D-117	-0.4169763922691345	Do not store the product refrigerated .
P-117	-0.4815 -0.1402 -0.1922 -0.2923 -0.0898 -2.6408 -0.1410 -0.0837 -0.1663 -0.2014 -0.1576
S-192	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-192	The product may not be returned to refrigerated storage again .
H-192	-0.4169763922691345	Do not store the product refrigerated .
D-192	-0.4169763922691345	Do not store the product refrigerated .
P-192	-0.4815 -0.1402 -0.1922 -0.2923 -0.0898 -2.6408 -0.1410 -0.0837 -0.1663 -0.2014 -0.1576
S-218	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-218	The product may not be returned to refrigerated storage again .
H-218	-0.4169763922691345	Do not store the product refrigerated .
D-218	-0.4169763922691345	Do not store the product refrigerated .
P-218	-0.4815 -0.1402 -0.1922 -0.2923 -0.0898 -2.6408 -0.1410 -0.0837 -0.1663 -0.2014 -0.1576
S-142	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-142	The product may not be returned to refrigerated storage again .
H-142	-0.4169763922691345	Do not store the product refrigerated .
D-142	-0.4169763922691345	Do not store the product refrigerated .
P-142	-0.4815 -0.1402 -0.1922 -0.2923 -0.0898 -2.6408 -0.1410 -0.0837 -0.1663 -0.2014 -0.1576
S-113	Erkrankungen der Haut und des Unterhautzellgewebes
T-113	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-113	-0.11166764795780182	Skin and subcutaneous tissue disorders
D-113	-0.11166764795780182	Skin and subcutaneous tissue disorders
P-113	-0.1031 -0.1295 -0.1563 -0.1012 -0.0700 -0.0800 -0.1315 -0.1192 -0.1152 -0.0465 -0.1034 -0.1841
S-92	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-92	The product may not be returned to refrigerated storage again .
H-92	-0.4169763922691345	Do not store the product refrigerated .
D-92	-0.4169763922691345	Do not store the product refrigerated .
P-92	-0.4815 -0.1402 -0.1922 -0.2923 -0.0898 -2.6408 -0.1410 -0.0837 -0.1663 -0.2014 -0.1576
S-9	Weitere Informationen sind der Packungsbeilage zu entnehmen .
T-9	For more information , see the Package Leaflet .
H-9	-0.16639243066310883	For more information , see the Package Leaflet .
D-9	-0.16639243066310883	For more information , see the Package Leaflet .
P-9	-0.1227 -0.4154 -0.1022 -0.1408 -0.1766 -0.1362 -0.3167 -0.1140 -0.0996 -0.0401 -0.1005 -0.2454 -0.1529
S-315	Die Einnahme kann unabhängig von den Mahlzeiten erfolgen .
T-315	The tablet may be taken with or without food .
H-315	-0.47180697321891785	Taking can be done regardless of meals .
D-315	-0.47180697321891785	Taking can be done regardless of meals .
P-315	-0.4980 -1.6382 -0.3039 -0.3259 -0.9460 -0.1503 -0.0675 -0.1612 -0.1553
S-304	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-304	The medicine can only be obtained with a prescription .
H-304	-0.141370490193367	The medicine can only be obtained with a prescription .
D-304	-0.141370490193367	The medicine can only be obtained with a prescription .
P-304	-0.2777 -0.1565 -0.2166 -0.1484 -0.1421 -0.0424 -0.0859 -0.1258 -0.0534 -0.1494 -0.1570
S-71	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-71	The medicine can only be obtained with a prescription .
H-71	-0.141370490193367	The medicine can only be obtained with a prescription .
D-71	-0.141370490193367	The medicine can only be obtained with a prescription .
P-71	-0.2777 -0.1565 -0.2166 -0.1484 -0.1421 -0.0424 -0.0859 -0.1258 -0.0534 -0.1494 -0.1570
S-7	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-7	The medicine can only be obtained with a prescription .
H-7	-0.141370490193367	The medicine can only be obtained with a prescription .
D-7	-0.141370490193367	The medicine can only be obtained with a prescription .
P-7	-0.2777 -0.1565 -0.2166 -0.1484 -0.1421 -0.0424 -0.0859 -0.1258 -0.0534 -0.1494 -0.1570
S-88	Positiver Test auf Antikörper gegen Faktor VIII
T-88	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-88	-0.19766847789287567	Positive test for antibodies to factor VIII
D-88	-0.19766847789287567	Positive test for antibodies to factor VIII
P-88	-0.1217 -0.0945 -0.1145 -0.1304 -0.0924 -0.0985 -0.4479 -0.6668 -0.1942 -0.0598 -0.1537
S-0	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-0	The medicine can only be obtained with a prescription .
H-0	-0.141370490193367	The medicine can only be obtained with a prescription .
D-0	-0.141370490193367	The medicine can only be obtained with a prescription .
P-0	-0.2777 -0.1565 -0.2166 -0.1484 -0.1421 -0.0424 -0.0859 -0.1258 -0.0534 -0.1494 -0.1570
S-138	Erkrankungen der Haut und des Unterhautzellgewebes
T-138	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-138	-0.11166764795780182	Skin and subcutaneous tissue disorders
D-138	-0.11166764795780182	Skin and subcutaneous tissue disorders
P-138	-0.1031 -0.1295 -0.1563 -0.1012 -0.0700 -0.0800 -0.1315 -0.1192 -0.1152 -0.0465 -0.1034 -0.1841
S-114	Hämatokritabfall Auffällige Laborwerte
T-114	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-114	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
D-114	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
P-114	-1.0344 -0.0897 -0.1229 -0.0802 -0.0315 -0.3111 -3.1222 -0.8280 -0.6032 -0.1293 -0.0683 -0.1179 -0.1887
S-187	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-187	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-187	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
D-187	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
P-187	-1.1958 -0.0754 -0.0994 -0.1728 -0.0928 -0.2574 -0.0925 -0.1648 -0.7598
S-215	Hämatokritabfall Auffällige Laborwerte
T-215	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-215	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
D-215	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
P-215	-1.0344 -0.0897 -0.1229 -0.0802 -0.0315 -0.3111 -3.1222 -0.8280 -0.6032 -0.1293 -0.0683 -0.1179 -0.1887
S-189	Hämatokritabfall Auffällige Laborwerte
T-189	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-189	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
D-189	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
P-189	-1.0344 -0.0897 -0.1229 -0.0802 -0.0315 -0.3111 -3.1222 -0.8280 -0.6032 -0.1293 -0.0683 -0.1179 -0.1887
S-164	Hämatokritabfall Auffällige Laborwerte
T-164	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-164	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
D-164	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
P-164	-1.0344 -0.0897 -0.1229 -0.0802 -0.0315 -0.3111 -3.1222 -0.8280 -0.6032 -0.1293 -0.0683 -0.1179 -0.1887
S-139	Hämatokritabfall Auffällige Laborwerte
T-139	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-139	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
D-139	-0.5174970626831055	Haematocrit waste Abnormal laboratory values
P-139	-1.0344 -0.0897 -0.1229 -0.0802 -0.0315 -0.3111 -3.1222 -0.8280 -0.6032 -0.1293 -0.0683 -0.1179 -0.1887
S-163	Erkrankungen der Haut und des Unterhautzellgewebes
T-163	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-163	-0.11166764795780182	Skin and subcutaneous tissue disorders
D-163	-0.11166764795780182	Skin and subcutaneous tissue disorders
P-163	-0.1031 -0.1295 -0.1563 -0.1012 -0.0700 -0.0800 -0.1315 -0.1192 -0.1152 -0.0465 -0.1034 -0.1841
S-213	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-213	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-213	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
D-213	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
P-213	-1.1958 -0.0754 -0.0994 -0.1728 -0.0928 -0.2574 -0.0925 -0.1648 -0.7598
S-188	Erkrankungen der Haut und des Unterhautzellgewebes
T-188	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-188	-0.11166764795780182	Skin and subcutaneous tissue disorders
D-188	-0.11166764795780182	Skin and subcutaneous tissue disorders
P-188	-0.1031 -0.1295 -0.1563 -0.1012 -0.0700 -0.0800 -0.1315 -0.1192 -0.1152 -0.0465 -0.1034 -0.1841
S-162	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-162	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-162	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
D-162	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
P-162	-1.1958 -0.0754 -0.0994 -0.1728 -0.0928 -0.2574 -0.0925 -0.1648 -0.7598
S-137	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-137	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-137	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
D-137	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
P-137	-1.1958 -0.0754 -0.0994 -0.1728 -0.0928 -0.2574 -0.0925 -0.1648 -0.7598
S-112	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-112	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-112	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
D-112	-0.3233964741230011	Uncommon Uncommon Uncommon Uncommon
P-112	-1.1958 -0.0754 -0.0994 -0.1728 -0.0928 -0.2574 -0.0925 -0.1648 -0.7598
S-214	Erkrankungen der Haut und des Unterhautzellgewebes
T-214	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-214	-0.11166764795780182	Skin and subcutaneous tissue disorders
D-214	-0.11166764795780182	Skin and subcutaneous tissue disorders
P-214	-0.1031 -0.1295 -0.1563 -0.1012 -0.0700 -0.0800 -0.1315 -0.1192 -0.1152 -0.0465 -0.1034 -0.1841
S-210	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-210	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-210	-0.3211238384246826	Diarrhoea Abdominal pain Nausea Vomiting
D-210	-0.3211238384246826	Diarrhoea Abdominal pain Nausea Vomiting
P-210	-0.9818 -0.0286 -0.0904 -0.0177 -2.0922 -0.0134 -0.0522 -0.0910 -0.6222 -0.0502 -0.1180 -0.0327 -0.1010 -0.2043
S-184	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-184	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-184	-0.3211238384246826	Diarrhoea Abdominal pain Nausea Vomiting
D-184	-0.3211238384246826	Diarrhoea Abdominal pain Nausea Vomiting
P-184	-0.9818 -0.0286 -0.0904 -0.0177 -2.0922 -0.0134 -0.0522 -0.0910 -0.6222 -0.0502 -0.1180 -0.0327 -0.1010 -0.2043
S-308	Tablette mit veränderter Wirkstofffreisetzung
T-308	EU/ 1/ 07/ 399/ 001 EU/ 1/ 07/ 399/ 002 EU/ 1/ 07/ 399/ 003 EU/ 1/ 07/ 399/ 004 EU/ 1/ 07/ 399/ 005 EU/ 1/ 07/ 399/ 006
H-308	-1.0043137073516846	Changed drug release tablet
D-308	-1.0043137073516846	Changed drug release tablet
P-308	-4.6863 -0.1457 -0.2253 -1.7371 -0.7129 -0.1717 -0.0928 -0.2627
S-159	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-159	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-159	-0.3211238384246826	Diarrhoea Abdominal pain Nausea Vomiting
D-159	-0.3211238384246826	Diarrhoea Abdominal pain Nausea Vomiting
P-159	-0.9818 -0.0286 -0.0904 -0.0177 -2.0922 -0.0134 -0.0522 -0.0910 -0.6222 -0.0502 -0.1180 -0.0327 -0.1010 -0.2043
S-253	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-253	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-253	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-253	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-253	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-258	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-258	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-258	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-258	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-258	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-233	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-233	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-233	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-233	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-233	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-236	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-236	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-236	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-236	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-236	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-241	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-241	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-241	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-241	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-241	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-249	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-249	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-249	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-249	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-249	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-278	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-278	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-278	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-278	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-278	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-244	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-244	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-244	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-244	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-244	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-261	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-261	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-261	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-261	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-261	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-266	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-266	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-266	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-266	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-266	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-269	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-269	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-269	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-269	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-269	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-274	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-274	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-274	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-274	-0.0619262233376503	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-274	-0.0451 -0.0183 -0.0691 -0.1250 -0.0972 -0.1510 -0.0345 -0.0541 -0.0587 -0.0265 -0.0438 -0.1429 -0.0754 -0.0787 -0.0641 -0.0985 -0.0292 -0.0339 -0.0141 -0.0267 -0.0017 -0.0513 -0.1121 -0.0782 -0.0787 -0.0568 -0.0286 -0.0518 -0.0045 -0.0134 -0.0563 -0.0570 -0.1663
S-243	79 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-243	73 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-243	-0.24143598973751068	79 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-243	-0.24143598973751068	79 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-243	-1.7358 -0.0580 -0.0679 -0.0227 -0.0437 -0.0236 -0.0733 -0.0396 -0.0223 -0.0178 -0.0144 -0.0140 -0.1342 -0.0713 -2.2558 -0.0546 -0.0782 -0.0575 -0.2038 -0.1630 -0.0636 -0.3438 -0.5549 -0.0614 -0.0631 -0.0235 -0.2055 -0.2930
S-252	83 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-252	77 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-252	-0.2322782576084137	83 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-252	-0.2322782576084137	83 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-252	-1.4626 -0.0603 -0.0995 -0.0289 -0.0431 -0.0235 -0.0765 -0.0365 -0.0166 -0.0180 -0.0138 -0.0138 -0.1411 -0.0711 -2.2211 -0.0553 -0.0816 -0.0552 -0.2271 -0.1725 -0.0643 -0.3874 -0.5134 -0.0576 -0.0640 -0.0237 -0.2021 -0.2735
S-235	75 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-235	69 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-235	-0.23729267716407776	75 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-235	-0.23729267716407776	75 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-235	-1.7400 -0.0657 -0.0840 -0.0318 -0.0397 -0.0214 -0.0753 -0.0439 -0.0183 -0.0164 -0.0137 -0.0149 -0.1643 -0.0747 -2.0811 -0.0571 -0.0788 -0.0563 -0.1681 -0.1502 -0.0649 -0.3607 -0.5612 -0.0624 -0.0644 -0.0237 -0.2062 -0.3047
S-268	91 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-268	85 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-268	-0.1980927735567093	91 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-268	-0.1980927735567093	91 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-268	-0.6781 -0.0727 -0.0950 -0.0298 -0.0571 -0.0246 -0.0838 -0.0231 -0.0169 -0.0163 -0.0127 -0.0140 -0.1311 -0.0711 -2.0388 -0.0512 -0.0768 -0.0549 -0.1969 -0.1610 -0.0649 -0.3790 -0.5586 -0.0611 -0.0624 -0.0242 -0.2025 -0.2879
S-277	95 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-277	89 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-277	-0.21053959429264069	95 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-277	-0.21053959429264069	95 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-277	-1.0592 -0.0873 -0.0769 -0.0284 -0.0375 -0.0222 -0.0679 -0.0423 -0.0155 -0.0158 -0.0134 -0.0146 -0.1362 -0.0708 -2.0133 -0.0536 -0.0813 -0.0538 -0.2099 -0.1597 -0.0646 -0.3719 -0.5575 -0.0612 -0.0621 -0.0247 -0.1994 -0.2939
S-260	87 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-260	81 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-260	-0.2104979306459427	87 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-260	-0.2104979306459427	87 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-260	-1.1000 -0.0453 -0.0798 -0.0241 -0.0442 -0.0234 -0.0793 -0.0274 -0.0146 -0.0169 -0.0138 -0.0140 -0.1221 -0.0604 -1.9688 -0.0553 -0.0821 -0.0575 -0.2391 -0.1750 -0.0633 -0.4469 -0.5380 -0.0594 -0.0620 -0.0231 -0.2016 -0.2564
S-297	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
T-297	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <<unk>> 354 533 6100
H-297	-0.22151833772659302	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
D-297	-0.22151833772659302	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
P-297	-0.4100 -0.1695 -0.0943 -0.1805 -1.3055 -1.6021 -0.0981 -0.1837 -0.1183 -0.0558 -0.0842 -0.1387 -0.1120 -0.2464 -0.0739 -0.0837 -0.1005 -0.1611 -0.0673 -0.0566 -0.1496 -0.0694 -0.1373 -0.0659 -0.1225 -0.0983 -0.1498 -0.1278 -0.1613
S-283	WAS IST ADVATE UND WOFÜR WIRD ES ANGEWENDET ?
T-283	WHAT ADVATE IS AND WHAT IT IS USED FOR
H-283	-0.07924337685108185	WHAT ADVATE IS AND WHAT IT IS USED FOR
D-283	-0.07924337685108185	WHAT ADVATE IS AND WHAT IT IS USED FOR
P-283	-0.1024 -0.0505 -0.1018 -0.1703 -0.0925 -0.0885 -0.0460 -0.0526 -0.0982 -0.0239 -0.0764 -0.0525 -0.0570 -0.0413 -0.0598 -0.1110 -0.1223
S-279	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-279	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-279	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-279	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-279	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-240	78 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-240	72 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-240	-0.08832535147666931	78 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-240	-0.08832535147666931	78 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-240	-1.3158 -0.0958 -0.1055 -0.0179 -0.0533 -0.0196 -0.0205 -0.0741 -0.0462 -0.0535 -0.0447 -0.0627 -0.1641 -0.0058 -0.0442 -0.0184 -0.0244 -0.1020 -0.0585 -0.0397 -0.0054 -0.0203 -0.0233 -0.0637 -0.0551 -0.0567 -0.0561 -0.0429 -0.0519 -0.0557 -0.0037 -0.0362 -0.0319 -0.1331
S-276	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-276	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-276	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-276	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-276	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-232	74 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-232	68 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-232	-0.08626216650009155	74 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-232	-0.08626216650009155	74 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-232	-1.3060 -0.1012 -0.1111 -0.0190 -0.0532 -0.0187 -0.0191 -0.0700 -0.0412 -0.0489 -0.0426 -0.0576 -0.1501 -0.0060 -0.0404 -0.0182 -0.0239 -0.0889 -0.0566 -0.0391 -0.0045 -0.0188 -0.0220 -0.0647 -0.0546 -0.0539 -0.0526 -0.0435 -0.0480 -0.0569 -0.0032 -0.0356 -0.0316 -0.1312
S-267	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-267	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-267	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-267	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-267	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-248	82 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-248	76 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-248	-0.08506925404071808	82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-248	-0.08506925404071808	82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-248	-1.2433 -0.1118 -0.1057 -0.0173 -0.0513 -0.0194 -0.0193 -0.0812 -0.0396 -0.0531 -0.0406 -0.0580 -0.1438 -0.0047 -0.0438 -0.0180 -0.0237 -0.0935 -0.0603 -0.0383 -0.0048 -0.0187 -0.0218 -0.0645 -0.0557 -0.0545 -0.0574 -0.0450 -0.0457 -0.0548 -0.0032 -0.0371 -0.0308 -0.1320
S-257	86 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-257	80 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-257	-0.08857078105211258	86 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-257	-0.08857078105211258	86 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-257	-1.3764 -0.1142 -0.1013 -0.0153 -0.0526 -0.0204 -0.0187 -0.0702 -0.0387 -0.0518 -0.0438 -0.0555 -0.1410 -0.0050 -0.0419 -0.0180 -0.0227 -0.0961 -0.0566 -0.0399 -0.0045 -0.0169 -0.0210 -0.0657 -0.0569 -0.0575 -0.0520 -0.0453 -0.0478 -0.0568 -0.0032 -0.0386 -0.0311 -0.1340
S-265	90 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-265	84 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-265	-0.06697704643011093	90 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-265	-0.06697704643011093	90 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-265	-0.6972 -0.1022 -0.0882 -0.0162 -0.0500 -0.0200 -0.0170 -0.0611 -0.0367 -0.0452 -0.0428 -0.0519 -0.1544 -0.0037 -0.0380 -0.0168 -0.0231 -0.0976 -0.0576 -0.0402 -0.0039 -0.0175 -0.0207 -0.0649 -0.0551 -0.0554 -0.0511 -0.0464 -0.0436 -0.0572 -0.0034 -0.0347 -0.0310 -0.1323
S-273	94 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-273	88 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-273	-0.08100306242704391	94 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-273	-0.08100306242704391	94 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-273	-1.1235 -0.1136 -0.1160 -0.0172 -0.0505 -0.0198 -0.0156 -0.0622 -0.0339 -0.0447 -0.0416 -0.0576 -0.1499 -0.0041 -0.0413 -0.0185 -0.0230 -0.0933 -0.0583 -0.0401 -0.0040 -0.0181 -0.0234 -0.0643 -0.0583 -0.0590 -0.0519 -0.0418 -0.0482 -0.0579 -0.0033 -0.0361 -0.0308 -0.1321
S-19	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-19	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden . Circulating vitamin D3 is bound to vitamin D-binding protein .
H-19	-0.2216476947069168	Circulating vitamin D3 is bound to vitamin D-binding protein .
D-19	-0.2216476947069168	Circulating vitamin D3 is bound to vitamin D-binding protein .
P-19	-0.4010 -0.1190 -0.1158 -0.1133 -0.1070 -0.1432 -0.1560 -0.1310 -0.4698 -0.2144 -0.7931 -0.1729 -0.5827 -0.0740 -0.0846 -0.1360 -0.0764 -0.1654 -0.1556
S-270	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-270	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-270	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-270	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-270	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-259	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-259	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-259	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-259	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-259	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-262	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-262	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-262	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-262	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-262	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-203	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-203	Factor VIII level required ( % or IU/ dl )
H-203	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
D-203	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
P-203	-1.0810 -0.0960 -0.0370 -0.1398 -1.4524 -0.4824 -0.9443 -0.4989 -0.9090 -0.2355 -0.0485 -0.0879 -0.4705 -0.1462 -0.1374 -0.1311 -0.1046 -0.1695 -0.0910 -0.0257 -0.1474 -0.1895
S-32	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-32	Circulating vitamin D3 is bound to vitamin D-binding protein .
H-32	-0.2216476947069168	Circulating vitamin D3 is bound to vitamin D-binding protein .
D-32	-0.2216476947069168	Circulating vitamin D3 is bound to vitamin D-binding protein .
P-32	-0.4010 -0.1190 -0.1158 -0.1133 -0.1070 -0.1432 -0.1560 -0.1310 -0.4698 -0.2144 -0.7931 -0.1729 -0.5827 -0.0740 -0.0846 -0.1360 -0.0764 -0.1654 -0.1556
S-76	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-76	Factor VIII level required ( % or IU/ dl )
H-76	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
D-76	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
P-76	-1.0810 -0.0960 -0.0370 -0.1398 -1.4524 -0.4824 -0.9443 -0.4989 -0.9090 -0.2355 -0.0485 -0.0879 -0.4705 -0.1462 -0.1374 -0.1311 -0.1046 -0.1695 -0.0910 -0.0257 -0.1474 -0.1895
S-103	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-103	Factor VIII level required ( % or IU/ dl )
H-103	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
D-103	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
P-103	-1.0810 -0.0960 -0.0370 -0.1398 -1.4524 -0.4824 -0.9443 -0.4989 -0.9090 -0.2355 -0.0485 -0.0879 -0.4705 -0.1462 -0.1374 -0.1311 -0.1046 -0.1695 -0.0910 -0.0257 -0.1474 -0.1895
S-128	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-128	Factor VIII level required ( % or IU/ dl )
H-128	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
D-128	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
P-128	-1.0810 -0.0960 -0.0370 -0.1398 -1.4524 -0.4824 -0.9443 -0.4989 -0.9090 -0.2355 -0.0485 -0.0879 -0.4705 -0.1462 -0.1374 -0.1311 -0.1046 -0.1695 -0.0910 -0.0257 -0.1474 -0.1895
S-153	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-153	Factor VIII level required ( % or IU/ dl )
H-153	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
D-153	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
P-153	-1.0810 -0.0960 -0.0370 -0.1398 -1.4524 -0.4824 -0.9443 -0.4989 -0.9090 -0.2355 -0.0485 -0.0879 -0.4705 -0.1462 -0.1374 -0.1311 -0.1046 -0.1695 -0.0910 -0.0257 -0.1474 -0.1895
S-254	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-254	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-254	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-254	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-254	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-178	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-178	Factor VIII level required ( % or IU/ dl )
H-178	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
D-178	-0.3466168940067291	Necessary factor VIII- plasma level ( % or IU/ dl )
P-178	-1.0810 -0.0960 -0.0370 -0.1398 -1.4524 -0.4824 -0.9443 -0.4989 -0.9090 -0.2355 -0.0485 -0.0879 -0.4705 -0.1462 -0.1374 -0.1311 -0.1046 -0.1695 -0.0910 -0.0257 -0.1474 -0.1895
S-234	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-234	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-234	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-234	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-234	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-237	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-237	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-237	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-237	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-237	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-242	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-242	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-242	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-242	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-242	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-245	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-245	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-245	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-245	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-245	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-251	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-251	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-251	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-251	-0.10346751660108566	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-251	-0.0656 -0.1471 -0.1230 -0.0613 -0.1337 -0.0348 -0.0802 -0.1123 -0.0847 -0.0899 -0.1354 -0.1211 -0.0384 -0.2184 -0.0654 -0.0887 -0.0456 -0.0968 -0.1088 -0.0569 -0.0852 -0.1207 -0.2125 -0.1565
S-6	Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-6	Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu )
H-6	-0.39658623933792114	Filmtablet For oral use Blister ( Aclar/ PVC/ aluminium )
D-6	-0.39658623933792114	Filmtablet For oral use Blister ( Aclar/ PVC/ aluminium )
P-6	-1.9302 -1.0418 -0.5107 -1.4701 -0.3501 -0.4235 -0.1720 -0.1370 -0.2768 -0.1543 -0.2390 -0.1361 -0.1281 -0.1342 -0.1441 -0.1539 -0.1503 -0.1197 -0.0610 -0.1519 -0.4436
S-34	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-34	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-34	-0.1349656581878662	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-34	-0.1349656581878662	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-34	-0.2308 -0.1305 -0.1588 -0.0737 -0.1478 -0.1497 -0.1319 -0.0930 -0.1411 -0.1525 -0.1238 -0.1529 -0.0547 -0.1733 -0.1811 -0.1296 -0.0901 -0.1198 -0.1099 -0.1543
S-21	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-21	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-21	-0.1349656581878662	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-21	-0.1349656581878662	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-21	-0.2308 -0.1305 -0.1588 -0.0737 -0.1478 -0.1497 -0.1319 -0.0930 -0.1411 -0.1525 -0.1238 -0.1529 -0.0547 -0.1733 -0.1811 -0.1296 -0.0901 -0.1198 -0.1099 -0.1543
S-11	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-11	ADROVANCE reduces the risk of vertebral and hip fractures .
H-11	-0.22515280544757843	ADROVANCE reduces the risk of vertebral and hip fractures .
D-11	-0.22515280544757843	ADROVANCE reduces the risk of vertebral and hip fractures .
P-11	-0.0687 -0.0730 -0.1481 -0.1019 -0.0893 -1.7165 -0.0908 -0.1424 -0.0976 -0.1739 -0.7397 -0.0597 -0.0483 -0.1216 -0.1970 -0.0840 -0.1572 -0.0751 -0.1611 -0.1573
S-319	Desloratadin und Pseudoephedrin gehen in die Muttermilch über .
T-319	Desloratadine and pseudoephedrine are both excreted in breast milk .
H-319	-0.3120671510696411	Desloratadine and pseudoephedrine are released into human milk .
D-319	-0.3120671510696411	Desloratadine and pseudoephedrine are released into human milk .
P-319	-0.2995 -0.0377 -0.1151 -0.4271 -0.2138 -0.1394 -0.1392 -0.2330 -0.1430 -0.0472 -0.1246 -0.0695 -0.1080 -0.1529 -2.8141 -0.3798 -0.2869 -0.2081 -0.1540 -0.1484
S-22	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-22	ADROVANCE reduces the risk of vertebral and hip fractures .
H-22	-0.22515280544757843	ADROVANCE reduces the risk of vertebral and hip fractures .
D-22	-0.22515280544757843	ADROVANCE reduces the risk of vertebral and hip fractures .
P-22	-0.0687 -0.0730 -0.1481 -0.1019 -0.0893 -1.7165 -0.0908 -0.1424 -0.0976 -0.1739 -0.7397 -0.0597 -0.0483 -0.1216 -0.1970 -0.0840 -0.1572 -0.0751 -0.1611 -0.1573
S-229	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
T-229	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-229	-0.13175205886363983	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
D-229	-0.13175205886363983	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
P-229	-0.1717 -0.1447 -0.1577 -0.0892 -0.1959 -0.0964 -0.3084 -0.0912 -0.1057 -0.1200 -0.0782 -0.1236 -0.0957 -0.0629 -0.1222 -0.1193 -0.0435 -0.0872 -0.2414 -0.1803
S-299	Internationaler Freiname ( INN ) : Contusugene Ladenovec
T-299	International non-proprietary name ( INN ) : contusugene ladenovec
H-299	-0.301018625497818	International Freiname ( INN ) : Contusugene Ladenovec
D-299	-0.301018625497818	International Freiname ( INN ) : Contusugene Ladenovec
P-299	-0.7426 -1.8653 -0.1310 -0.1535 -0.1593 -0.0982 -0.1140 -0.1480 -0.1532 -0.2074 -0.2628 -0.1029 -0.0666 -0.5699 -0.1455 -0.1081 -0.1228 -0.2673
S-294	4 D-85716 Unterschleißheim Tel : <unk> 49 89 31 701
T-294	4 D-85716 Unterschleißheim Tel : <<unk>> 49 89 31 701
H-294	-0.18202078342437744	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
D-294	-0.18202078342437744	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
P-294	-1.0206 -0.1368 -0.1312 -0.1427 -0.1254 -0.1376 -0.0990 -0.2069 -0.2093 -0.3909 -0.0412 -0.1444 -0.0217 -0.0733 -0.0716 -0.1191 -0.1216 -0.0811 -0.1841
S-298	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-298	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-298	-0.17306067049503326	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-298	-0.17306067049503326	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-298	-0.7720 -0.2715 -0.2059 -0.0830 -0.1042 -0.1502 -0.1284 -0.2147 -0.1662 -0.0137 -0.2672 -0.0792 -0.1525 -0.1530 -0.0894 -0.0418 -0.1158 -0.0900 -0.1893
S-295	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-295	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-295	-0.17306067049503326	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-295	-0.17306067049503326	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-295	-0.7720 -0.2715 -0.2059 -0.0830 -0.1042 -0.1502 -0.1284 -0.2147 -0.1662 -0.0137 -0.2672 -0.0792 -0.1525 -0.1530 -0.0894 -0.0418 -0.1158 -0.0900 -0.1893
S-255	300 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-255	300 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-255	-0.31109389662742615	300 IU/ ml after reconstitution Specific activity : ca .
D-255	-0.31109389662742615	300 IU/ ml after reconstitution Specific activity : ca .
P-255	-0.0432 -0.1306 -0.1543 -0.1836 -0.0533 -0.8551 -0.1491 -0.0502 -0.3332 -0.0357 -0.1181 -0.1570 -2.0720 -0.1923 -0.1389
S-246	200 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-246	200 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-246	-0.32344022393226624	200 IU/ ml after reconstitution Specific activity : ca .
D-246	-0.32344022393226624	200 IU/ ml after reconstitution Specific activity : ca .
P-246	-0.2792 -0.1271 -0.1532 -0.1807 -0.0538 -0.8363 -0.1515 -0.0482 -0.2985 -0.0370 -0.1140 -0.1582 -2.0857 -0.1890 -0.1391
S-238	100 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-238	100 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-238	-0.31455591320991516	100 IU/ ml after reconstitution Specific activity : ca .
D-238	-0.31455591320991516	100 IU/ ml after reconstitution Specific activity : ca .
P-238	-0.1870 -0.1273 -0.1458 -0.1831 -0.0493 -0.7954 -0.1400 -0.0478 -0.3033 -0.0374 -0.1167 -0.1555 -2.1016 -0.1882 -0.1401
S-263	400 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-263	400 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-263	-0.3081499934196472	400 IU/ ml after reconstitution Specific activity : ca .
D-263	-0.3081499934196472	400 IU/ ml after reconstitution Specific activity : ca .
P-263	-0.0629 -0.1287 -0.1559 -0.1836 -0.0536 -0.7813 -0.1440 -0.0489 -0.3286 -0.0359 -0.1169 -0.1580 -2.0851 -0.1998 -0.1390
S-271	600 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-271	600 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-271	-0.32004469633102417	600 IU/ ml after reconstitution Specific activity : ca .
D-271	-0.32004469633102417	600 IU/ ml after reconstitution Specific activity : ca .
P-271	-0.1833 -0.1322 -0.1415 -0.1805 -0.0553 -0.8674 -0.1462 -0.0480 -0.3231 -0.0350 -0.1140 -0.1566 -2.0816 -0.1927 -0.1433
S-1	Durch die Verminderung der Harnsäureproduktion kann Adenuric die
T-1	By reducing the production of uric acid , Adenuric can reduce levels of uric acid in the blood and keep them low , stopping crystals from building up .
H-1	-0.4793035089969635	By reducing uric acid production , Adenuric acid may reduce the
D-1	-0.4793035089969635	By reducing uric acid production , Adenuric acid may reduce the
P-1	-0.5485 -0.4328 -0.1433 -0.0786 -0.0329 -0.1980 -0.2736 -0.2149 -0.1829 -0.0536 -0.1177 -0.6563 -2.3690 -0.9289 -0.3208 -1.1169
S-230	50 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-230	50 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-230	-0.3158758282661438	50 IU/ ml after reconstitution Specific activity : ca .
D-230	-0.3158758282661438	50 IU/ ml after reconstitution Specific activity : ca .
P-230	-0.0863 -0.1288 -0.1558 -0.1861 -0.0494 -0.8248 -0.1364 -0.0466 -0.3078 -0.0366 -0.1162 -0.1572 -2.1734 -0.1950 -0.1376
2021-01-24 03:24:38 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-24 03:24:38 | INFO | fairseq_cli.generate | Translated 320 sentences (4832 tokens) in 2.8s (113.34 sentences/s, 1711.47 tokens/s)
2021-01-24 03:24:38 | WARNING | root | That's 100 lines that end in a tokenized period ('.')
2021-01-24 03:24:38 | WARNING | root | It looks like you forgot to detokenize your test data, which may hurt your score.
2021-01-24 03:24:38 | WARNING | root | If you insist your data is detokenized, or don't care, you can suppress this message with '--force'.
Generate test with beam=5: BLEU = 33.91 73.1/60.4/51.8/43.9 (BP = 0.602 ratio = 0.663 hyp_len = 2871 ref_len = 4328)


###############################################################################
Peregrine Cluster
Job 17612065 for user 's3475743'
Finished at: Sun Jan 24 03:24:39 CET 2021

Job details:
============

Job ID              : 17612065
Name                : g_EMEA15_short
User                : s3475743
Partition           : gpu
Nodes               : pg-gpu39
Number of Nodes     : 1
Cores               : 12
State               : COMPLETED
Submit              : 2021-01-24T01:27:48
Start               : 2021-01-24T03:23:41
End                 : 2021-01-24T03:24:39
Reserved walltime   : 23:55:00
Used walltime       : 00:00:58
Used CPU time       : 00:00:17 (efficiency:  2.58%)
% User (Computation): 68.67%
% System (I/O)      : 31.33%
Mem reserved        : 32G/node
Max Mem used        : 1.53G (pg-gpu39)
Max Disk Write      : 40.96K (pg-gpu39)
Max Disk Read       : 2.30M (pg-gpu39)
Average GPU usage   : No GPU metrics available (pg-gpu39)


Acknowledgements:
=================

Please see this page for information about acknowledging Peregrine in your publications:

https://wiki.hpc.rug.nl/peregrine/introduction/scientific_output

################################################################################
